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1. Introduction: 
 
1.1 Endometrial carcinoma: 
The carcinoma is the disease that refers to unregulated cell growth which could 
develop in any tissue type with the ability to invade neighboring organs and 
could metastasize to distant organs (Hanahan and Weinberg, 2011). Transition 
from normal cells to cancer cells requires gaining the six hall markers of the 
cancer which include: firstly, uncontrolled growth, secondly, insensitive to tumor 
suppressors, thirdly, resistance to programmed cell death, fourthly, immortality, 
fifthly, activation of angiogenesis and lastly, triggering metastasis which makes 
the difference between the malignant and benign (Hanahan and Weinberg, 
2011). Endometrial carcinoma (EnCa) is an epithelial cancer which arises from 
the endometrium with a potential to invade the myometrium of the uterus or/ 
and the cervix (Torre et al., 2015). 
1.1.1 Incidence and survival 
Endometrial carcinoma, which arises from the endometrium, is a frequent 
reproductive carcinoma in females and accounts for around 95% of the uterine 
cancers (Torre et al., 2015). Uterine sarcoma, which arises from the 
myometrium surrounding the endometrium, is much rarer type and counts 
around 5% of the cases (Torre et al., 2015). The incidence changes based on 
the region and the country, for example its incidence rate in developing 
countries is several times less than in Caucasia (North America and Europe) 
where EnCa is considered as the most frequent carcinoma in women after 
mammary, non/small cell lung and bowel (colorectal) cancers (Parkin et al., 
1999). Global Cancer Statistics in 2012 reported that yearly, endometrial 
carcinoma is diagnosed in 320,000 women worldwide and led to 76,000 deaths 
in that year (Fig1.1-1). In Canada & USA, EnCa is considered as the eighth 
most common reason of death and 9,000 women die in Europe each year from 
endometrial carcinoma (Amant et al., 2005). Most patients are diagnosed after 
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the onset of menopause (Amant et al., 2005). Often, the cases are diagnosed in 
the early-stage: Probably; that is because of the early appearance of the cancer 
symptoms. Despite the advanced techniques for early detection, mortality rate 
remains the same without increase of survival rates. 
 
 
 
Figure1.1-1. The yearly incidence of endometrial carcinoma worldwide. 
Each year 320 000 cases are diagnosed and 76,000 will die from Endometrial 
cancer worldwide. This figure is drawn by me based on the following articels 
(Torre et al., 2015), (Parkin et al., 1999) and (Amant et al., 2005). 
 
1.1.2 Types of the Endometrial cancer 
80-90% of EnCa is differentiated based on histologic properties into endometrial 
carcinoma Type I (T1), which is also called endometrioid because of the 
histological similarity between this type and the endometrium, is usually 
detected in the early stage of the cancer (Duong et al., 2011). Women with 
EnCa Type II (T2; non-endometrioid), which counts 10-20% of the cases, are 
usually diagnosed with an older age compared to women with EnCa Type I 
(Duong et al., 2011). EnCa TI, is oestrogen dependant and occurs due to 
unopposed (stimulation of) oestrogen that leads to hyperplasia of the 
endometrium (Buchanan et al., 2009). EnCa TII is non-oestrogen dependent 
and is associated with endometrial atrophy (Amant et al., 2005; Duong et al., 
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2011). The most invasive of subtype EnCa TII is uterine serous cancer 
(Hendrickson et al., 1982). The first type of EnCa TI is more likely in Caucasian 
females. However, EnCa TII is more likely in African females, according to the 
American College of Obstetricians and Gynecologist (Hendrickson et al., 1982). 
Fig 1.1-2 shows the types of EnCa. 
 
 
 
 
 
 
 
 
 
Figure 1.1-2 Types of endometrial carcinoma. This figure is drawn by me 
based on (Buchanan et al., 2009) and (Amant et al., 2005; Duong et al., 2011) 
and (Hendrickson et al., 1982). 
1.1.3 Staging endometrial carcinoma  
Staging of endometrial carcinoma can be detected only surgically because 20% 
of the cases that is staged clinically were incorrect (Savelli et al., 2008). 
International Federation of Gynecology & Obstetrics (FIGO; Table1.1) describes 
the clinical presentation of EnCa. FIGO staging should be preceded by 
preoperative evaluation included physical examination and chest radiology. 
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Table1.1-1 EnCa FIGO staging, adapted from (figo, 2015) 
 
1.1.4 Risk Factors: 
Some of the risk factors can be changed such as smoking and obesity in some 
cases. Other risk factors can’t be changed, like increasing age and family 
history (Ali, 2013). Not all females with these predisposing factors will get EnCa. 
On the other hand, some women with the EnCa don’t have any known risk 
factors (Ali, 2013). 
Risk factors of endometrial carcinoma are divided into two groups: factors 
increasing risk of endometrial carcinoma and factors decrease risk of 
endometrial carcinoma (Ali, 2013). 
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1.1.4.1 Factors increasing risk of endometrial 
carcinoma: 
Long term of unopposed Estrogen: 
In the reproductive age, estrogen is secreted primarily by the ovaries, and also 
from adipose tissue and adrenal glands (Hawkins and Matzuk, 2008). During 
proliferative phase in the normal menstrual cycle, estrogen levels begin to 
increase leading to increasing in thickness of the endometrial lining. The 
proliferative process associated with estrogen includes the endometrial stroma 
and the glands (Hawkins and Matzuk, 2008). In the post-ovulatory 
(progesterone dependant) phase of the (menstrual) cycle, progesterone levels 
rise leading to glycogen and mucus secretion. At the end of this phase, with the 
absence of pregnancy and with the accompanying drops of the both hormones, 
the endometrium will shrink and shed. Without the opposing factor of 
progesterone, surplus estrogen promotes angiogenesis and endometrial cell 
proliferation (Hawkins and Matzuk, 2008) that may cause cancer. Previously, 
Estrogen Replacement Therapy (ERT) was prescribed to oppose the symptoms 
associated with the postmenopausal age without progesterone. This long term 
treatment of estrogen increased the risk of developing endometrial carcinoma 
about 17% per year (Weiderpass et al., 1999). Adding progesterone to oppose 
estrogen, which is called menopausal hormone therapy (HRT), decreases the 
chance of developing EnCa when compared with ERT (Weiderpass et al., 1999) 
(Trabert et al., 2013). HRT could increase the risk of developing endometrial 
cancer only after 10 years or more of use (Pike et al., 1997). 
 
Obesity and Diabetes: 
Obesity is a high risk factor not only for many diseases like cardiovascular 
disease but also for number of cancers including colorectal, pancreatic, breast 
and endometrial carcinoma (Calle and Thun, 2004; Kulie et al., 2011; Schmandt 
et al., 2011). Adipose tissues are endocrine organs, that secretes Adiponectin, 
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which is an adipokine (cytokine secreted by the adipocytes)(Scherer et al., 
1995). This hormone is an anti-inflammatory, anti-metabolic and increases 
insulin sensitivity in the healthy adipose tissue (Hada et al., 2007; Tishinsky et 
al., 2012). Obese adipose tissues are hypertrophic and associated with 
inflammation. Together, this can lead to very low expression of adiponectin, 
which in turn decreases the insulin sensitivity and the anti-inflammatory effect of 
adiponectin and could lead to carcinogenesis (Nagaraju et al., 2016). Body 
Mass Index (BMI) ≥ 25kg/m2 have been shown in more than 50% of endometrial 
carcinoma patients (Amant et al., 2005; Reeves et al., 2007). The combination 
of high BMI and low Adiponectin levels increases the risk of endometrial 
carcinoma 6 fold (Kelesidis et al., 2006; Petridou et al., 2003). Insulin resistance 
reduces the activity of the liver and increases insulin-like-growth-factor (IGF) 
(Pollak, 2008). IGF decreases the cell apoptosis and increases the cell 
proliferation in the cancer (Gooch et al., 1999). Glucose can promote the 
production of the tumor cells as long as it is a source of energy (Vrachnis et al., 
2016). Diabetes mellitus (DM) is a major risk factor of endometrial carcinoma 
(Vrachnis et al., 2016). Diabetic compared to non-diabetic women have a 2-3 
fold increased risk factor to develop endometrial carcinoma (La Vecchia et al., 
1994). Obesity is found in most cases of DM Type 2 and it has been shown that 
diabetes associated with obesity increases the risk factor of developing 
endometrial carcinoma to 6 fold (Friberg et al., 2007). This risk increases to 10 
times when these patients never do physical exercise (Friberg et al., 2007). 
 
Increasing age: 
It is known that the endometrial carcinoma is the cancer of postmenopausal 
women (Amant et al., 2005). 90% of the cases were diagnosed after the age of 
50 years with a peak in the age 60-70s (Amant et al., 2005; Schottenfeld, 1995). 
This peak could change from geographical region to another (Ali, 2013). Less 
than 14% of the cases are diagnosed in women under 40 years old (Fadhlaoui 
et al., 2010). 
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Early menarche and late menopause: 
Many female cancers like breast (ductal or lobular), ovarian and endometrial 
carcinomas are associated to the young age of the first menstruation and 
advanced age of menopause (Rice, 2010) (Zucchetto et al., 2009) due to more 
exposure time of oestrogen due to more menstrual cycles (Brinton et al., 1992). 
Turkish women with early age of menarche (under fifteen) developed 
endometrial carcinoma 9 times more compared to women with menarche after 
the age fifteen (Reis and Beji, 2009). Researchers compared between the 
women who had menopause aged 50 -54 years and women whose menopause 
took place before 45 years of age. The first group had a 67% higher risk of 
EnCa. Women which developed menopause later (over 55 years old) had a 
79% higher risk (Wolfman et al., 2010). 
 
Familal history: 
A familial history in EnCa in first blood female family members (mother, sister, 
and daughter) occurs only in 5% of the cases. (Ali, 2013; Parazzini et al., 1994). 
The familal history of EnCa, but not the breast or ovarian cancer, increases the 
risk 3 fold compared to women without family history of EnCa (Ali, 2013; Gruber 
and Thompson, 1996). Non-presence of EnCa in Turkish families was a 
decreased-risk factor of the same cancer (Reis and Beji, 2009). 
 
History of breast cancer:  
Breast cancers rarely metastasize to the endometrium (Huo et al., 2015) but a 
primary endometrial carcinoma can develop in women with breast cancer 
(Bland et al., 2009). Maybe it is because of the shared risk factors. Women with 
breast cancer have an increased risk of developing a serous endometrial 
cancer (Gehrig et al., 2004). 
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Tamoxifen: 
Tamoxifen (TAM) specifically modulates the estrogen receptors, in the breast 
tissue it works as an antagonist, whilst in the endometrium it is an agonist (Gallo 
and Kaufman, 1997). Since 1970, TAM has been used as an anti-tumor 
adjuvant therapy against positive estrogen receptor breast cancer (Grilli, 2006). 
Long-term (≥ 36 months) use TAM for previous breast cancer increases the risk 
of developing different abnormalities in the endometrium, including endometrial 
carcinoma (Neven et al., 1998) but not during the first three years of TAM 
treatment. Raloxifene hydrochloride is also another modulator of estrogen 
receptor which is indicated for preventing and treating the osteoporosis 
following the post menopause. This modulator does not have the same 
stimulating effect on the endometrium that TAM has, and is safe to be 
prescribed for five years (Jolly et al., 2003). 
 
Infertility and nulliparity:  
Infertile females experience an increased risk to develop EnCa than fertile 
females (Brinton et al., 2005). The majority of young infertile women who suffer 
from chronic anovulation, leads to elevated levels of the serum estrogen that 
increases the risk to develop endometrial carcinoma (Ali, 2013). Poly cystic 
ovarian syndrome (PCO) is a hormonal syndrome which is mostly presented as; 
high levels of serum androgen, obesity and chronic anovulation - leads to the 
accumulation of unopposed oestrogen. This increases the risk of developing 
endometrial carcinoma (Spritzer, 2014). PCO occurs in 5–10% of females 
reproductive/child-bearing age. It is the most frequent cause of primary 
infertility, due to anovulation (Group, 2012). Almost 30% of the endometrial 
carcinoma patients have PCO in premenopausal age (Navaratnarajah et al., 
2008).  
Oligo- and nulliparity increase the risk factor of endometrial carcinoma up to 
four fold (Ali, 2013). As well, the age at the first live birth is another risk factor to 
develop endometrial carcinoma. Females who delivered their first baby at 
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middle age (≥ 30 years) were at 40% lower risk compared to teenagers (13-19 
years) (Wernli et al., 2006). There is no significantly difference between females 
who have one live baby and multi- live births to develop endometrial carcinoma 
(Wernli et al., 2006). 
 
Race: 
Few studies have been reported the differences of risks among the ethnic 
groups. In America, it was shown that white women are at a higher risk to 
develop endometrial carcinoma type I compared to other races (Buchanan et 
al., 2009;Setiawan et al., 2007). The rate of endometrial cancer incidence 
between 1998 and 2002 in African-Americans was only 74% of in the American 
white women (Farley et al., 2007; Setiawan et al., 2007). Whilst, the mortality 
rate in the African women was 79% of whites. Maybe this increase of the deaths 
was associated with the endometrial carcinoma in black women is related to the 
late diagnose of this cancer and treatment (Farley et al., 2007). 
 
1.1.4.2 Factors decreasing risk of endometrial 
carcinoma: 
Combined-oral-contraceptive COC: 
Recently, it has been recommended that the duration of progesterone that 
protects the endometrium is 12-14 days each month (Grady and Ernster, 1997). 
Combined oral contraceptive (COC) that contains estrogen and progesterone 
decreases the incidence of endometrial carcinoma (Buchanan et al., 2009; 
Deligeoroglou et al., 2003). 
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Smoking: 
Many studies showed smoking as a protector factor against endometrial 
carcinoma (Buchanan et al., 2009; Viswanathan et al., 2005). In 2005, Zhou 
and colleagues analysed 34 studies and have concluded to decrease in the risk 
of endometrial carcinoma up to 30% associated to cigarette smoking (Zhou et 
al., 2008). The chance of developing EnCa was reduced in those who smoke ≥ 
35 cigarettes a day and among women who smoke for ≥ 40 years (Viswanathan 
et al., 2005). This relation between smoking and decreased risk of endometrial 
carcinoma was reported only in postmenopausal women (Ali, 2013). Maybe the 
effect of smoking as an antiestrogen and reduction the age of menopause 
associated with smoking can explain the protective role of smoking against 
endometrial carcinoma (Ali, 2013; Baron et al., 1990). 
 
Life style: 
In 2011, Terry P and colleagues showed in their study that a good life style 
could decrease the risk of endometrial carcinoma: increasing physical exercise 
significantly decreased the risk of developing endometrial carcinoma 
independently of weight (Terry et al., 1999). Low intake of fruits and vegetables 
increased the risk while there was no difference associated to alcohol intake 
(Ali, 2013; Terry et al., 1999). 
 
1.1.5 Symptoms of endometrial carcinoma 
Abnormal uterine bleeding (AUB) is the most frequent manifestation in EnCa. 
Atypical vaginal and/or AUB occurs in 90% of cases & will present with this 
clinical symptom (Amant et al., 2005). All postmenopausal women who suffer 
from this symptom with predisposing factors should have further examination 
and diagnostic assessment (Amant et al., 2005). 5-10% of postmenopausal 
women with abnormal uterine bleeding could develop endometrial carcinoma. 
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This percentage increases in the presence of the endometrial carcinoma risk 
factors (Gredmark et al., 1995). 
 
1.1.6 Diagnosis 
Physical examination and History: When a postmenopausal woman come to 
the clinic with abnormal uterine bleeding, the medical history and the physical 
examination, is taken. Any abnormality in the uterus, ovaries, vagina or pelvis is 
included in the preoperative evaluation, as well the patient history should be 
taken to evaluate the risk factors (Committee on Practice, 2012). 
Transvaginal Ultrasound (TVU) and magnetic resonance imaging (MRI): 
Transvaginal Ultrasound is not an invasive test and is considered as the first 
step in case of diagnosing the cause of postmenopausal bleeding (American 
College of and Gynecologists, 2009b) as it offers the chance to check the 
thickness of the endometrium. When TV sonography is not possible because of 
marked obesity for example, an alternative method is indicated (American 
College of and Gynecologists, 2009a). Depth of invasion and metastases into 
the cervix and lymph nodes play critical role in MRI staging (Meissnitzer and 
Forstner, 2016). 
Endometrial Biopsy: Endometrial thickness less than 4mm has a negative 
chance of developing malignancy, according to a Nordic multicenter study, and 
does not require endometrial sampling (Karlsson et al., 1995). The sensitivity of 
the blind endometrial biopsy, specifically by Pippelle device, has been 
calculated to detect endometrial carcinoma 99% in postmenopausal women and 
up to 90% in premenopausal women with specificity up to 98% (Dijkhuizen et 
al., 2000). Blind biopsy is more useful in global lesions than in focal one 
(Goldstein, 2009). It is indicated to take 3mm to exclude the endometrial 
carcinoma in postmenopausal women (Timmermans et al., 2010). Discomfort, 
bleeding and infection could be caused by endometrial biopsy (2002). 
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Hysteroscop and Saline Infusion Sonography (SIS): Sterile saline (NaCl, 
0.9%) is pumped into the uterus for better visualization of the cavity and its 
structures. It is indicated when the ultrasound suggests a focal lesion which 
could contain malignancy or when an endometrial biopsy showed normal or for 
a non-diagnostic sample (Buchanan et al., 2009; Clark et al., 2002; de Kroon et 
al., 2003). Saline Infusion sonography or hysteroscopy could still be a risk factor 
as there is a potential of peritoneal contamination by the cancer cells after the 
procedure. 
Pap smears: Normal cervical smears do not exclude endometrial carcinoma. 
However, this method is not a sensitive procedure for EnCa, only when it shows 
abnormality, then it is associated with high grades of EnCa (Gu et al., 2001). 
 
1.1.7 Treatment of endometrial carcinoma 
Preoperative Staging: Preoperative staging is an important step before 
surgery to define the risk based on the invasion to the cervix and the 
myometrium, and the lymph node metastases and to define the right surgical 
assessment. Both TVU and MRI are used for preoperative staging. MRI is 
sometimes not available because of high cost, so when TVU does gives not 
high quality images, then MRI is offered (Savelli et al., 2008). To detect the 
lymph node metastases MRI, if not available the CT, are used (Morice et al., 
2016). 
Surgery: For endometrial carcinoma stage I, total hysterectomy with fallopian 
tubes and the ovaries is indicated and affective alone in 75% of the cases 
(Morice et al., 2016). Only 0.8% Women with low risks and tumor ≤ 2cm and 
myometrial invasion ≤ 50% could have lymph metastases. Lymphadenectomy 
has no effect on the survival or the cancer recurrence in the early stage of 
disease (Frost et al., 2015). Lymphadenectomy of the pelvic nodes and 
paraoortic nodes is indicated in the presence of any of the following features: 
serous, clear cell or high-grade histology, > 50% myometrial invasion, Tumor 
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size > 2 cm (Ytre-Hauge et al., 2015). Minimally invasive techniques 
(laparoscopy or robot-assisted surgery) are less invasive than laparotomy and 
need shorter stay in the hospital and causes fewer complications than 
laparotomy (Janda et al., 2010). 
Adjuvant therapies: 
Radiation: Radiation therapy (RT) for endometrial carcinoma significantly 
decreased the chances of prolapses and is indicated as a 6 weeks 
postoperative treatment (Ahmad et al., 1995). Women with noninvasive 
endometrial carcinoma are in a low risk of recurrent cancer and RT is not 
indicated to be included in their treatment (Keys et al., 2004). Primary RT is an 
option for medically inoperable patients with survival fewer than 16% 
(Podzielinski et al., 2012). 
Chemotherapy: Women with high-risk endometrial carcinoma are indicated for 
chemotherapy with or without RT (Colombo et al., 2013). 
 
 
 
 
 
 
 
14 
 
 1.2 Dysfunctional uterus bleeding (DUB) and LEFTY2 
1.2.1 Dysfunctional uterus bleeding (DUB): 
The endometrium is a unique tissue in the female body that it sheds monthly 
during menstruation. This process which leads to monthly menstrual bleeding is 
still not totally understood. Many factors affect menstrual bleeding. The most 
important implicators are the ovarian steroids (Oestrogen and Progesterone) 
(Papageorgiou et al., 2009; Tabibzadeh, 2011). In the case that implantation 
does not occur, serum levels of progesterone (in the late secretory phase) 
decreases leading to menstrual bleeding (Hawkins and Matzuk, 2008). The 
term dysfunctional uterine bleeding (DUB) is abnormal endometrial bleeding 
with the absence of systemic or structural disease (Bravender and Emans, 
1999). Almost half of the women who suffer from DUB are 40 to 50 years old 
(March, 1998) and occurs often when ovulation does not happen (Bayer and 
DeCherney, 1993; March, 1998). DUB in adolescents is usually associated with 
the immaturity of the hypothalamic-pituitary-ovarian axis which in turn leads to 
lack of the luteinizing hormone (LH) then the secretory phase in the menstrual 
cycle does not occur (Bayer and DeCherney, 1993). Similarly DUB in peri-
menopausal women is secondary to aging of the ovary which leads to decrease 
of the estrogen production, LH surge and the secretory phase do not develop so 
the endometrium is exposed to the estrogen without opposed progesterone 
which leads to DUB (Bravender and Emans, 1999; Hickey and Fraser, 2000). 
This DUB could occur during the secretory phase due to insufficiency of the 
luteal phase. DUB in most cases is associated with the anovulation and 
especially chronic anovulation which could lead in high risk of endometrial 
carcinoma (Bayer and DeCherney, 1993) and an endometrial biopsy is 
indicated in women over 35 years old with DUB (Bradley and Gueye, 2016). 
DUB can be treated medically with combination oral contraceptives or progestin 
alone (Bradley and Gueye, 2016; Hickey and Fraser, 2000). Surgical 
procedures including hysterectomy are indicated in case of medicaments 
failure, other symptoms such as pain occur and the patient’s request for surgery 
(Farrell, 2004). 
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1.2.2 LEFTY2, TGFβ4, the endometrial bleeding-
associated factor (EBAF) 
In 1983, Transforming Growth Factor-beta (TGF-β) was first described (Assoian 
et al., 1983). It is a multifunctional protein that controls proliferation, 
differentiation and is  involved in other functions in many cell types (Assoian et 
al., 1983). LEFTY2 (TGFβ4; EBAF) is a member of TGF β superfamily (Meno et 
al., 1996; Tabibzadeh et al., 1997; Thisse and Thisse, 1999,Kothapalli et al., 
1997). During the development of the vertebrae embryonic morphogenesis, the 
fetus body plan is associated with three axes: the dorsovenrtal, the 
anterioposterior and the Lefty-Right axes to achieve the normal developing of 
the embryo in three dimensional spaces (Mercola and Levin, 2001). It has been 
reported that mutations in the gene that encoded LEFTY2 have been 
associated with left-right axis malformations, specifically in the heart and the 
lungs. In both mice and humans, the gene of LEFTY2 is localized to 
chromosome 1. The locus contains two murine genes Lefty1 and Lefty2 with the 
same transcriptional orientation (Kosaki et al., 1999). Human LEFTY1 and 
LEFTY2 are close to each other. LEFTY2 shares 91% sequence identity and 
331 amino acids with LEFTY2. Both of them block the Nodal signaling and 
prevent the assembly of an functioning receptor complex (Nodal-Activin) (Schier 
and Shen, 2000). Meno C and his colleagues in 1998 reported that the role of 
LEFTY2 is to restrict the expression of LEFTY2 and Nodal to the left side (Meno 
et al., 1998). Human LEFTY2 polypeptide is secreted as a 42-kDa precursor 
susceptible to proteolytic cleavage (Ulloa et al., 2001). This protein presents in 
normal endometrium and its levels increase about 100-fold at the perimenstrual 
phase and the menstrual endometria (Cornet et al., 2002;Tabibzadeh et al., 
2000). Previously it has been reported, that in ex vivo increasing of LEFTY2 
occurs with the absence of steroid hormones leading to increasing in MMP3 
and MMP7 in an explant from proliferative endometria, while progesterone 
controls both the presence of LEFTY2 and its effect on MMP7. This may explain 
the dramatic increase of LEFTY2 at the perimenstrual phase is pointing that 
LEFTY2 is a key regulator for the endometrium breaking down and the 
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menstrual bleeding by stimulating the production of MMPs (Cornet et al., 2002). 
It has been shown that the levels of LEFTY2 decreases during the implantation 
window in the fertile subjects (Tabibzadeh, 2011; Tabibzadeh et al., 2000) while 
in the infertile women the levels of LEFTY2 were dysregulated in the window of 
implantation (Tabibzadeh et al., 2000). So LEFTY2 is not only associated with 
infertility but also with the abnormal uterine bleeding (Kothapalli et al., 
1997;Salker et al., 2011; Tabibzadeh and Kothapalli, 1996; Tang et al., 2005). 
 
1.2.3 LEFTY2 inhibits Activin A 
Activins, which belong to TGF-β family, are involved in several biological 
processes such as; cell growth, cell differentiation and cell death (Guo and 
Wang, 2009). The human endometrium locally secretes the activins proteins to 
modulate the stromal decidualization, a critical step before implantation. The 
interaction between activins and other regulating processes leads to this effect 
(Florio et al., 2010). By interacting with serine-threonine receptor kinases, 
Activin A can signal to its targets. First, Activin A binds to ActRII receptor, 
causing the phosphorylation and thus stimulation of ALK4 receptor (Welt et al., 
2002). Activated ALK4 phosphorylates Smad proteins (Smad2 and Smad3) 
(Derynck et al., 1998). Then, they form complexes with Smad4 and translocate 
into the nucleus and affect specific genes (Welt et al., 2002). LEFTY2 and 
Activin A share 65% structural similarity. LEFTY2 can interact with the ActRII 
blocking phosphorylation of Smads and thus impeding downstream factors or 
pathways (Welt et al., 2002). Fig 1.2-1 shows the negative role of Lefty2 on 
Activin A signaling. 
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Figure 1.2-1 LEFTY2 inhibits Activin A signaling. (A) Dimerization of Activin 
firstly interacts with ActRII, which mediates and activates (phosphorylation) Alk4 
leading to activation of Smads 2/3 forming a complex with Smad 4. affecting 
downstream genes. (B) LEFYT2 inhibits this pathway by binding to the receptor 
II and preventing the phosphorylation of Smad proteins. This figure is drawn by 
me based on (Guo and Wang, 2009)(Florio et al., 2010)(Welt et al., 
2002)(Derynck et al., 1998) 
 
1.3  LEFTY2 as a strong suppressor of tumor cells 
In normal cells TGF-β inhibits the normal cell proliferation by arresting the cell in 
stage G1, so that TGF-β encourages cells to differentiate or to apoptosize 
(Ravitz and Wenner, 1997) and TGF-β is a powerful regulator of the production 
of extra cellular matrix (ECM) which affects the adhesive properties of the ECM. 
TGF-β increases the production of ECM proteins and cell-adhesion proteins, 
and decreases the production of ECM degradation enzymes (Massague, 1990). 
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In cancer cells, if a mutation occurs in the TGF-β signaling pathway, this can 
lead to residency in the cells, leading to uncontrolled proliferation. Increased 
secretion of TGF-β can lead to increased angiogenesis leading to aggressive 
cancer (Gordon and Blobe, 2008). 
Nodal, a protein belonging to TGF β (Oshimori and Fuchs, 2012), is very 
important during embryo development. It acts as an organizing signal to start 
the axis formation and the nodal signaling is involved also in the L/R patterning 
(Baker et al., 2008). Nodal has been shown as a cancer marker in several 
tumors such as mammary carcinoma (Strizzi et al., 2012), and not only as a 
diagnostic marker but also as a therapeutic target in some cancers like 
melanoma (Strizzi et al., 2009). In prostate cancer cells, it has been shown that 
the reactivation of Nodal signaling promotes cellular proliferation of tumour cells 
(Lawrence et al., 2011). It has been further shown that the intensity of Nodal 
staining was upregulated in the advanced and invasive stages of BrCa 
comparing with the early stages and the treatment by blocking antibodies of the 
nodal signaling in vitro reduced the proliferation of the cells and increased 
apoptosis (Strizzi et al., 2012). LEFTY2 has been shown as an inhibitor of nodal 
signaling (Miyata et al., 2012; Sun et al., 2014). It has been shown that LEFTY2 
was absent in normal tissues such as stomach, liver kidney, breast, ovaries and 
fallopian tubes while it presents in many tumor tissues such as 
adenocarcinomas in colonic and ovarian adenocarcinomas. This expression 
was absent in the adenocarcinomas of colon metastatic to the liver (Tabibzadeh 
et al., 1997). A previous study investigated the anti-cancer role of LEFTY2 in 
Human Adult Liver Stem Cells HLSC, and showed that the conditioned medium 
(CM) of HLSC inhibited the in vitro growth of the cells and promoted the 
apoptosis of the cells that expressed a deregulated Nodal pathway. These 
effects were associated to LEFTY2 (Cavallari et al., 2013). LEFTY2 mediates 
growth inhibition and suppressed cells proliferation in pancreatic cells (Miyata et 
al., 2012). 
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1.4 The cytoskeleton and its regulators: 
1.4.1 Rac1 and PAK1, key regulators of actin 
reorganization: 
The cytoskeleton is like the “backbone of the body”, it holds the organelles in 
the cell together, connects the cell to the external environment, maintains the 
cell shape and gives it the ability to move when it is necessary (Fletcher and 
Mullins, 2010). The cytoskeleton is not a fixed structure but it is a dynamic one 
whose components could polymerize or depolymerize according to the case 
(Fletcher and Mullins, 2010). The cytoskeleton consists of three different 
filaments: microtubules, actin and intermediate filaments. The reorganization of 
the actin and microtubules filaments occurs by the two different processes: 
polymerization and depolymerization- and gives the cytoskeleton the dynamic 
structure (Fletcher and Mullins, 2010). Microtubules are the stiffest filament in 
the cytoskeleton and play the most major role in the stabilization of extended 
cells, including nerve cells (Zheng et al., 1993). They polymerize vertically when 
cells become columnar as during neurulation (Burnside, 1971). Actin filaments 
are less stiff than the microtubules, but the concentrations of the crosslinking 
proteins that bind to the filaments change the stiffness (Pollard and Cooper, 
2009). Assembly of actin proteins is responsible of the cell movement within the 
cell and the whole cell over the surface, for example during the embryo 
development the cells change their location. The immune cells also migrate 
searching for the pathogens. Even cancer cells migrate using the same 
mechanism (Pollard and Cooper, 2009). The crawling process of the cell 
involves four steps: 1) extension of the actin filaments which applies the force 
on the cell membrane leading to protrusion or lamellipodium, 2) new adhesion 
to the surface, 3) translocation and 4) deadhesion (Pollard and Borisy, 2003). 
Shaped like a double helix, actin filaments consist of polymers of globular 
monomeric sub-units G-actin which polymerize into polymeric state or 
filamentous actin F-actin (Carlier et al., 2015;Fletcher and Mullins, 2010). The 
movement is based on the actin exchanges between these two states. G-actin 
binds to ATP or ADP.  ATP-actin polymerizes faster in the positive filament end 
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which is called barbed end than the negative one which is called the pointed 
end. This polymerization of actin leads to elongation of F-actin. The elongation 
continues as long as the rate of the elongation is bigger than the loss of ADP-
actin from the pointed end (De La Cruz and Gardel, 2015;Pollard and Borisy, 
2003). Fig 1.4-1 shows the Actin polymerization. 
 
 
 
 
 
 
Figure 1.4-1 Actin polymerization. Monomer actin binds with ATP (white) to 
polymerize and be added to the plus end. ATP hydrolyzes by releasing Pi. 
Actin-ADP (red) depolymerizes from the minus end. This figure is drawn by me 
based on (Pollard and Cooper, 2009,Pollard and Borisy, 2003,Carlier et al., 
2015; Fletcher and Mullins, 2010,De La Cruz and Gardel, 2015; Pollard and 
Borisy, 2003) 
 
Cell shape maintenance, motility of the cells and the cell-cell adhesion are all 
processes requiring a dynamic reorganization in the cytoskeleton. This finding 
was investigated in different types of epithelial cells (Adams et al., 1998; Adams 
et al., 1996). The small G protein ras-related C3 botulinum toxin substrate 1 
(GTPase Rac1) belongs to the Rho family of Guanosine Triphosphatase 
(GTPases), which is known as a regulator of various signaling pathways that 
control the reorganization of the cytoskeleton to produce the stress fibers and 
leads to the formation of the filopodia and lamellipodium which has a major role 
in the beginning of cellular motility process (Nobes & Hall, 1995; Small et al., 
2002). In mammals, the Rho family contains 22 members. Rac1, Cdc42 and 
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RhoA are the most common members and are involved in most researches 
because of their crucial roles in the actin dynamic and cell migration and 
proliferation (Jaffe and Hall, 2005; Ridley, 2006). Table 1.4-1 shows the most 
common members of Rho Family and its effect on the actin filamenst. 
 
 
 
 
Table 1.4-1 The effect of the most common members of Rho family on the 
actin filaments. This figure is drawn by me based on (Adams et al., 1998; 
Adams et al., 1996,Nobes &  Hall, 1995; Small et al., 2002Jaffe & Hall, 2005; 
Ridley, 2006). 
 
Rho family members work as molecular switches. They change their states from 
(off) to (on) and the opposite by two opposing enzyme groups: guanine 
exchange factor (GEFs), GTPase-activating proteins (GAPs). The capabilty of 
tumour cells to invade other organs depends on their ability to move and cross 
the barriers which indeed require a high organization of the cytoskeleton 
(Yamaguchi and Condeelis, 2007). Rac1 overexpression is found in different 
types of cancers includes melanoma progression and metastasis (Bauer et al., 
2007) testicular cancer, gastric, squamous cell cancer and aggressive breast 
cancer tissues compared to normal tissues (Kamai et al., 2004; Parri and 
Chiarugi, 2010; Schnelzer et al., 2000). P21-activated kinase (PAK1) is an 
effector of Rac1. Membrane- bound Rac1-GTP inducts PAK by binding to their 
Cdc42-Rac1 interactive binding (CRIB) domain leading to auto-phosphorylation 
of PAK1(King et al., 2014). In normal endometrium, PAK1 level expression is 
higher in proliferative phase compared to secretory phase (Siu et al., 2015). 
PAK1 is significantly overexpressed in EnCa which suggests that PAK1 plays a 
role in the development of EnCa especially in post-menopausal women (Siu et 
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al., 2015). PAK1 has been shown as an important regulator of cytoskeleton 
dynamics, cells proliferation and apoptosis, and cells migration and motility 
(King et al., 2014; Ye and Field, 2012). 
Therefore Rac1 and PAK are suggested as therapeutic targets against cancer 
angiogenesis and metastasis (Bid et al., 2013; Senapedis et al., 2015). The 
next figure (Fig.1.4-2) shows the Rac1 and PAK1 signaling. 
 
Figure 1.4-2 Rac1 and PAK1 signaling. PAK proteins are influenced by Rac1 
and Cdc42. PAK1 takes part in cell migration, cell growth, focal adhesion and 
anti-apoptosis. This figure is drawn by me depending on (Yamaguchi and 
Condeelis, 2007,Bauer et al., 2007,Kamai et al., 2004; Parri and Chiarugi, 2010; 
Schnelzer et al., 2000 Siu et al., 2015 King et al., 2014; Ye and Field, 2012.Bid 
et al., 2013; Senapedis et al., 2015). 
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It has been shown that the acidosis in the microenvironment increases the 
metastatic capacity of the cancer cells (Cuvier et al., 1997). Na+/H+ exchanger 1 
(NHE1) is known as an important regulator of pHi in the tumor 
microenvironment and also has a major role in the organization of the 
cytoskeleton (Boyer & Tannock, 1992; Denker et al., 2000). Activation of NHE1 
increases in turn the capability of tumour cells to become highly invasive 
(Reshkin et al., 2000). Rac1 is a critcal regulator of NHE1 in BrCa. It has been 
shown that increasing levels of Rac1 in BrCa cells leaded to activation of NHE1, 
increasing in the cell motility and decreasing of F-actin (Paradiso et al., 2004). 
Applying a pharmacologic inhibitor of NHE1 on renal (epithelial) cells lead to 
downregulation of actin polymerization and migration of the cells (Klein et al., 
2000). LEFTY2 has a powerful effect on NHE1. It has been shown that LEFTY2 
downregulated the expression of NHE1 expression and the exchanger activity 
which leaded to downregulation of pHi in Ishikawa cells and cell volume (Salker 
et al., 2015). 
1.5 E-Cadherin and cell-cell junctions:   
Cells in multicellular organs connect to each other to maintain shape and 
structure (Bryant and Mostov, 2008). By the lateral surface, epithelial cells are 
connected to the neighbors by cell-cell junctions. Tight junctions act as a barrier 
to regulate the water and fluid movement (Aijaz et al., 2006). Desmosomes 
anchor the intermediate filaments to the plasma membrane giving mechanical 
strength to the tissues such as in epidermis and myocardia (Garrod and 
Chidgey, 2008; Johnson et al., 2014). Adherens junctions are formed basically 
from the classical adherens such as E-cadherin and bind directly to the actin 
cytoskeleton (Halbleib and Nelson, 2006; Tepass et al., 2001). E-cadherin is 
expressed from the early stages during the embryo development. E-cadherin 
deficient embryos failed to form the blastocyst cavity and died at implantation 
(Larue et al., 1994). In the tumor cells, this loss of intercellular adhesions is a 
result of reduction of intracellular E-cadherin function and leads to 
dedifferentiation, higher motility, invasiveness and distant metastasis 
(Birchmeier and Behrens, 1994). Some tumor cells once they are separated 
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from the primary tumor become unable to re-express E-cadherin protein, which 
confirms the role of E-cadherin in metastasis and cells migration (Bukholm et 
al., 2000). Forced expression of E-cadherin by E-cadherin cDNA transfection 
prevented the invasiveness of the tumor cells (Frixen et al., 1991). Fig1.5-1 
shows the cell junctions. 
 
 
Figure 1.5-1 Cell junctions. (A) cells of the epithelium: are joined to each other by 
adherens, tight junctions, desmosomes and the basal surface to the ECM providing the 
luminal shape and to regulate the exchange of the materials and the signals. (B) The 
Adherens junction between the epithelial cells and the focal adhesion with the ECM 
connect directly with the cytoskeleton. This figure is drawn by me depending on (Bryant 
and Mostov, 2008)(Aijaz et al., 2006)(Garrod and Chidgey, 2008; Johnson et al., 
2014)(Halbleib and Nelson, 2006; Tepass et al., 2001)(Larue et al., 1994) 
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The adhesions between the cells and the extra cellular matrix (ECM) are 
mediated through integrin receptors that bind to focal adhesion kinase FAK, a 
120 KDa protein and was given its name based on its localization in focal 
adhesion (Schaller et al., 1992). β-Integrin facilitates FAK auto phosphorylation 
at Y397 and supplies the mechanical connection between the cytoskeleton and 
the Integrins (Shi and Boettiger, 2003; Toutant et al., 2002). FAK integrin-
associated phosphorylation leads to FAK-Src complex which leads in turn to 
activate many other cellular pathways through protein phosphorylation, which 
are involved in many cellular functions such as such as cell growth, migration in 
normal and cancer cells, tumorigenesis, cell polarization and cell shape (Cohen 
and Guan, 2005; Guan et al., 1991; Mitra and Schlaepfer, 2006; Schlaepfer et 
al., 2004). High expression of FAK has been reported in many types of 
carcinomas such as squamous cell carcinoma, colonic, prostatic, BrCa and 
ovarian carcinoma (Aronsohn et al., 2003; Judson et al., 1999; Owens et al., 
1995; Tremblay et al., 1996). The overexpression of FAK in oesophageal 
squamous-cell cancer was related with the invasiveness and metastases into 
the lymph nodes (Miyazaki et al., 2003). Inhibition of FAK phosphorylation lead 
to suppression in cell proliferation and tumor growth in pancreatic 
neuroendocrine tumors (Moen et al., 2015) and induced the cell apoptosis 
(Shanthi et al., 2014). This overexpression of FAK in many types of cancers 
made it as a potential cancer therapeutic target (Shanthi et al., 2014) and its 
inhibitors as treatments of cancer metastasis (Shanthi et al., 2014). The 
Figure1.5-2 shows the FAK signaling. 
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Figure1.5-2 FAK signaling. Phosphorylation at Y397 in one of FAK activation 
pathway and the complex FAK-Src formation which leads to many proteins 
phosphorylation that takes part ia a variety of biological functions. FAK inhibition 
increases cell apoptosis & decreases cancer metastasis. This figure is drawn by me 
based on (Shi and Boettiger, 2003; Toutant et al., 2002)(Cohen and Guan, 2005; Guan 
et al., 1991; Mitra and Schlaepfer, 2006; Schlaepfer et al., 2004). (Moen et al., 
2015)(Shanthi et al., 2014).  
 
1.6 MicroRNAs (miRNA) 
Micro RNAs (miRNA) were first described in 1993 (Lee et al., 1993). It has been 
shown that LIN-4 gene encoded a protein that bound to 3’ Untranslated Region 
(3´ UTR) of LIN-14 message RNA (mRNA) and inhibited the translation of LIN-
14 (Lee et al., 1993). miRNAs are small encoding RNAs and 20-25 nucleotides 
long. They control multiple genes through binding to the 3´ UTR of mRNAs so 
they prevent the translation of this target RNA or directly they degrade the 
target. Single miRNA is not specific for one mRNA, it can be responsible for 
multiple messenger RNA (Christopher et al., 2016). MiRNAs are expressed in 
the most organisms including the viruses regulating the expressions of the 
genes which are involved in different biological processing in the organisms 
such as cell proliferation and motility (Christopher et al., 2016). Overexpression 
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and underexpression of miRNAs are associated with variety pathogenies 
including hepatitis C, inflammatory diseases and hepatocellular carcinoma. 
MiRNAs could be new therapeutic targets (Christopher et al., 2016). The figure 
1.6-1 shows the effect of miRNA on protein synthesis. 
 
Figure 1.6-1 miRNA prevents protein synthesis. The binding between mRNA 
and miRNA prevent the protein synthesis by one of two mechanisms: blocking the 
mRNA translation or degrading the target mRNA. This figure is drawn by me based on 
(Lee et al., 1993, Christopher et al., 2016) 
 
Many researchers have reported about the critical roles of miRNAs in the tumor 
metastasis and showed that miRNAs act as suppressors and/or sometimes 
promoters of cancer metastasis such as in BrCa (Asangani et al., 2008; Ma et 
al., 2007). Till now it is not obvious in which steps of metastasis process are 
these miRNAs are involved, but it has been shown that the member of the miR-
200 lineage has a major role as suppressors for Epithelial Mesenchymal 
Transition (EMT) through upregulation of E-Cadherin and inhibition the 
migration in breast cancer and HeLa cells (Korpal et al., 2008). The miR-200 
family has 5 members (miR-200a, -200b, -200c, -141, & -429) (Humphries and 
Yang, 2015). EMT is the mechanism that which the cells of epithelium gain the 
properties of mesenchymal cells by undergoing morphologic changes so it can 
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move and separate from the primary tumor and becomes more invasive (Han et 
al., 2013; Kong et al., 2011). This process includes actin cytoskeleton 
reorganization and loss of the cell-cell junctions characterized by down 
regulation of E-cadherin (Schmalhofer et al., 2009). Increasing evidences show 
the role of this process in the cancer metastasis (Hollier et al., 2009; Moustakas 
and Heldin, 2007). EMT is induced by many extracellular ligands including TGF-
β which plays a critical role to initiate this process in development and cancer by 
stimulating SMAD and non-SMAD pathways (Derynck et al., 2014). Zinc-Finger 
E-box Binding Homeobox (ZEB) can activate EMT by pressing the epithelial 
phenotype and activating the mesenchymal phenotype proteins. ZEB 
suppresses E-cadherin and tight junction proteins. By being a suppressor of 
junction proteins between cells and enhancing mesenchymal properties, ZEB is 
known as modulator of EMT (Abba et al., 2016). It has been reported that 
miRNA-200 members are inhibitors of EMT by targeting ZEB (Chen et al., 
2013). 
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Aim of the study: 
 
My aims in this thesis is to explore whether: 
 LEFTY2 has an effect on the actin polymerization of human endometrial 
carcinoma cells (Ishikawa) which could lead to dynamic changes in cell 
stiffness, area, volume and migration.  
 LEFTY2 regulates RAC1 expression and activity and PAK1 
phosphorylation in EnCa which play a critical role during the beginning 
of cell movement.  
 LEFTY2 affects the proliferation in human EnCa cells (Ishikawa). 
 LEFTY2 could affect focal adhesion kinase (FAK) phosphorylation. 
  LEFTY2 could affect miR-200 and E-Cadherin expression in Ishikawa 
cells leading to reduce of migration. 
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2. Materials and methods: 
2.1 Materials 
2.1.1 Treatments 
Name Concentration Manufacture Country 
LEFTY2 25 ng/ml R&D Systems Oxford, UK 
NSC 23766 
(RAC inhibitor) 100 µM Sigma 
Hannover, 
Germany 
IPA 3 
(PAK inhibitor) 50 μM TOCRIS bioscience 
Wiesbaden-
Nordenstadt, 
Germany 
PF 573228 
(FAK inhibitor) 50 μM TOCRIS bioscience 
Wiesbaden-
Nordenstadt, 
Germany 
Cytochalasin D 10 µM Sigma 
Hannover, 
Germany 
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2.1.2 Antibodies 
 
2.1.3 Cell line 
Cells Cells line 
Ishikawa Cells Epithelial Endometrial Carcinoma 
 
 
Antibody Dilution Manufacture Source 
Molecular 
weight 
E-Cadherin 1:1000 Cell Signaling Rabbit 135 KD 
Total FAK 1:1000 // // 125 KD 
pFAK 1:1000 // // 125 KD 
Total RAC1 1:1000 // // 21 KD 
pRAC1 1:1000 // // 28 KD 
Total PAK1 1:1000 // // 68 KD 
pPAK1 1:1000 // // 68 KD 
Pan-Actin 1:1000 // // 45 KD 
GAPDH 1:500 // // 37 KD 
Polyclonal 
Goat Anti-
rabbit IgG- 
HRP(2°AB) 
1:2000 Dako   
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2.1.4 Reagents  
 
 
 
Name Manufacture 
30% (w/v) Acrylamide National Diagnostic 
2-Butanol VWR 
Chloroform Sigma 
Dimethylsulfoxid  (DMSO) Carl Roth GmbH 
Isopropanol Sigma 
Methanol VWR 
Ethanol VWR 
TEMED Sigma 
Paraformaldehyde (PFA) // 
Sodium dodecyl sulphate (SDS) // 
Tris base // 
Triton X-100 // 
Tween 20 // 
Bradford // 
Glycine // 
Developer and Replenisher Kodak 
Fixer and Replenisher Sigma 
Propidium Iodide Staining Solution eBIOSCIENCE 
Annexin V conjugated // 
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2.1.5 Technical equipment and stock materials 
 
Name Manufacture and country 
Tissue culture plate 6, 96 well Fisher Scientific, Dreieich, Germany 
Eppendorf pipette 10-20, 200, 1000 µl Eppendorf AG, Hamburg, Germany 
Stripette® 5, 10, 25 ml Corning Incorporated, Corning NY, USA
Tissue Culture Flask 75 TPP from Sigma, Munich, Germany 
Sterile Tube 15, 50 ml Cell Star from Sigma, Munich, Germany
X-well Tissue Culture Chambers Sarstedt, Nümbrecht, Germany 
Vortex Genie Scientific Industries, Bohemia NY, USA 
Centrifuge RotiFix 32 Hettich Zentrifugen, Tuttlingen, Germany
Flow cytometry tubes BD Bioscience, Heidelberg, Germany 
Flow cytometry machine // 
miRNeasy Mini Kit Qiagen, Dusseldorf, Germany 
Real-Time PCR machine; BioRad 
iCycler iQTM  
Bio-Rad Laboratories, München, Germa
Gel cassettes Invitrogen, Karlsruhe, Germany 
Western blot module  The Invitrogen XCell II II™ 
96 well qPCR plates Peqlab, Erlangen, Germany 
qPCR Sel // 
Kodak film Sigma, Hannover, Germany 
Densitometer Quantity One BioRad, München, Germany 
Fixer  // 
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2.1.6 Cell Culture chemicals 
Name Manufacture 
Dulbecco’s modified eagles medium 
(DMEM) 
Invitrogen, Karlsruhe, Germany 
L-Glutamin, 200 Mm (X100) // 
Penicillin /10,000 U/ml)- streptomycin 
(10,000 µg/ml) solution (X100) 
Invitrogen,  
Foetal bovine serum (FBS) Invitrogen, Karlsruhe, Germany 
Trypsin-EDTA solution (X1) // 
Phosphate buffered saline (PBS) GIBCO, Carlsbad, Germany 
Fetal bovine serum (FBS) Sigma, Hannover, Germany 
 
2.1.7 Software 
Name Manufacture 
Microsoft office 2010 SP3 Microsoft corp. Redmond, USA. 
CFX Manager software Bio-Rad, München, Germany 
Image J US National Institutes of Health (NIH) 
Flowjo LLC Oregon, USA 
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2.1.8 Buffers and solutions 
 
Phosphate-Buffered Saline (PBS) 
140 mM NaCl 
2.5 mM KCl 
1.5 mM KH2PO4 
10 mM Na2HPO4  
Tris-Buffered Saline (TBS) 
130 mM NaCl 
20 mM Tris, pH 7.6 
 
TBS-Tween 20 (TBST) 
0.1% Tween 20 in TBS 
4% PFA (stored in 4 °C) 
4% PFA (w/v) in PBS 
Adjust to Ph 7.4 with NaOH 
Radio Immuno Precipitation Assay 
(RIPA) Buffer (stored in -20°C) 
1% NP-40 (v/v) 
1% Triton X-100 
150 mM NaCl 
2 mM NaF 
1% Sodium Deoxycholate (w/v) 
0.1% SDS (w/v) 
10 mM Tris, pH 8.8 
1 Complete Protease Inhibitor Cocktail 
Tablet per 50 ml Buffer 
Protein Loading Buffer (Laemmli 
Buffer) (stored in -20°C)  
50 mM Tris-HCl, pH 6.8 
50 mM Imidazole, pH 6.8 
1% (w/v) SDS 
10% (v/v) Glycerol 
2% (v/v) β -mercaptoethanol 
0.002 (w/v) Bromophenol Blue 
Western SDS Running Buffer 
250 mM Tris Base 
1.9 M Glycine 
1% (w/v) SDS 
 
Western Transfer Buffer 
250 mM Tris Base 
192 mM Glycine, pH 8.3 
20% (v/v) Ethanol 
 
Western Blocking Buffer and 
Secondary Antibody Incubation 
Solution (stored in 4 °C) 
5% (w/v) non-fat Milk in TBS-T  
Western Primary Antibody Incubation 
Solution 
3% (w/v) BSA in TBS-T 
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3.2  Methods: 
The methods described below were performed either by the manufcturers’ 
protocols or were described by the following 2 articles.  
1.LEFTY2 Controls Migration of Human Endometrial Cancer Cells via Focal 
Adhesion Kinase Activity (FAK) and miRNA-200a. Alowayed N, Salker MS, 
Zeng N, Singh Y, Lang F. Cell Physiol Biochem. 2016;39(3):815-26. doi: 
10.1159/000447792. Epub 2016 Aug 9. 
 
2.LeftyA decreases Actin Polymerization and Stiffness in Human Endometrial 
Cancer Cells.Salker MS, Schierbaum N, Alowayed N, Singh Y, Mack AF, 
Stournaras C, Schäffer TE, Lang F. Sci Rep. 2016 Jul 11;6:29370. doi: 
10.1038/srep29370. 
 
3.2.1  Cell culture 
The experiments of this study are based on Ishikawa Cell samples, a well 
differentiated endometrial carcinoma adherent cell model.  
Ishikawa cells were cultured in DMEM/F12 by Gibco ® without phenol red-free 
media, containing 10% fetal calf serum (FCS), 1% antibiotic/antimycotic solution 
and 0.25% L-Glutamine (Invitrogen, Karlsruhe, Germany). 
For passaging: Cells were passaged with the use of 2ml of 0.25% Trypsin-
EDTA (gibco®) 37 °C/ 5% CO2, incubated for 5 min then the flask was tapped 
gently to detach the cells. 8ml of 10% media was added which quenched the 
detachment reaction. Cells were then centrifuged (1000 r.p.m / 5 minutes) and 
the pellet was re-suspended in 10% media.  
Cells were placed in T75 flasks after counting the cells with the calculation: 
Total cells = number of cells/16 qm X 104 X dilution X Volume Per 1million cells, 
1 ml of 10% media was added. For cell culture, 1.5 ml of cells was added to 10 
ml of 10% media & incubated in T75 flask. For experiments, 100 µl of cells per 2 
ml of media per well & incubated for 48 hours before treating when necessary. 
Cells were incubated in Binder GmbH incubator: temperature 37 °C, CO2 
concentration 5% and Humidified. To inhibit growth of bacteria, viruses, algae, 
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fungi, and precipitation of inorganic salts, Aqua Clean by WAK - Chemie 
Medical GmbH was used (5ml/1liter Water Carl Roth GmbH) every 4 weeks. 
3.2.2 RNA isolation 
3.2.2.1 messenger RNA (mRNA) isolation 
Total mRNA from Ishikawa was extracted by using ice-cold Trizol (Invitrogen) 
based on a phenol-chloroform extraction protocol: Ishikawa cells were 
scratched by using 400 µl ice-cold Trizol and then transferred to 2ml Eppendorf 
sterile tubes. 200 µl ice-cold chloroform was added and then vortexed for 30 
seconds. The samples were kept at -80 °C for 20 minutes then defrosted. The 
samples were centrifuged at 13,000 revolution per minute (r.p.m) for 30 min at 4 
°C. Then an equal amount of ice-cold isopropanol was subsequently added to 
the newly formed clear layer (RNA). The samples were centrifuged at 13,000 
(r.p.m) for 15 min at 4 °C. The supernant was discarded and the white pellet 
was washed in 400 µl of ice-cold 70% Ethanol. The samples were centrifuged at 
13,000 (r.p.m) for 15 min at 4 °C then the pellet was left to air dry prior to being 
dissolved in 15µl distilled water. 
  
3.2.2.2 Micro RNA (miRNA) Isolation 
MiRNA was extracted from Ishikawa cultures based on Quick-Start protocol- 
Qiagen by using miRNeasy Mini Kit (Qiagen, Düsseldorf, Germany): 
700 µl QIAzol lysis Reagent was added to each sample. Then the homogenate 
was incubated at room temperature for 5 minutes. Then 200µl of chloroform 
was added and the tubes were securely closed. The tubes were vigorously 
shaken for 15 seconds then incubated at room temperature for 2-3 minutes. 
The samples were centrifuged at 12,000 (r.p.m) at 4 °C for 15 seconds. The 
upper aqueous phase was transferred to a new collection sterile tube. Next 1.5 
volume of 100% ethanol was added and mixed by pipetting up and down. 
Pipetted up to 700 µl sample into a RNeasy@ Mini column in a 2ml collection 
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tube. Then centrifuged at 12,000 (r.p.m) at 4 °C for 15 seconds. After that 700 
µl Buffer RWT was added to RNeasy Mini column and centrifuged at 12,000 
(r.p.m) at 4 °C for 15 seconds. 500 µl Buffer RPE as added to the RNeasy Mini 
column and centrifuged at 12,000 (r.p.m) at 4 °C for 15 seconds. 500 µl of 
Buffer RPE was added to the RNeasy Mini column then centrifuged at 12,000 
(r.p.m) at 4 °C for 2 minutes. The RNeasy Mini column was placed into a new 2 
ml collection tube. Then the samples were centrifuged at 12,000 (r.p.m) at room 
temperature for 3 minutes to further dry the membrane. Transfer the RNeasy 
Mini column to a new 1.5 ml collection tube. 30 µl RNase-free water was added 
directly to the RNeasy Mini column membrane and finally centrifuged at 12,000 
x g at room temperature for 1 min to elute. 
 
Figure 3.2-1 Messenger RNA isolation protocol. 
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3.2.3  cDNA synthesis 
3.2.3.1 From mRNA  
 RNA was extracted from treated and unstimulated Ishikawa Cells was 
quantified using a nano-drop BioPhotometer Plus (Eppendorf, Hamburg, 
Germany) after RNA dilution 1:69 in distilled water. The volume of RNA needed 
for 2μg of cDNA was calculated. To generate complimentary deoxyribonucleic 
acid cDNA from total RNA, the Superscript III First-Strand synthesis system for 
RT-PCR (Invitrogen) was used: 
 Total RNA was mixed with 1µl oligo (dt) and 1µl of dNTP  
and the volume made up to 11µl with distilled water. Then incubated at 65°C for 
5min and placed on ice for at least 1 min. 9.4 µl of the master mix was added to 
each RNA/primer mix. And incubated at 50°C for 50min and terminal at 85°Cfor 
5 min. cDNA samples were stored at -20°C. 
Reagent Volume 
10 x RT buffer 2µl 
25 mM MgCL2 4µl 
0.1 M DTT 2µl 
RNase Out (inhibitor) 1µl 
Super Script 0.4µl 
Table 3.2-1 The reaction mixture for 2µg of RNA. 
 
3.2.3.2 miRNA implication 
RNA was extracted from treated and unstimulated Ishikawa Cells was 
quantified using a nano-drop spectrophotometer and the volume of RNA 
needed for 1 μg of cDNA was calculated. The miRCURY LNA Universal RT 
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Reagent Volume 
5x RT buffer 1 µl 
Enzyme mix 0.5 µl 
mRNA (100ng) 1 µl 
Nuclease-free water 2.5 µl 
microRNA PCR protocol was used. Thaw gently the 5x RT Buffer and nuclease-
free water and immediately placed on ice. Directly before using, the Enzyme 
mix was removed from freezer and mix by flicking the tube and placed on ice 
too. The required amount of the reagents was prepared as it is shown in table 
3.2-2:  
 
 
 
 
 
 
Table3.2-2 The reaction mixture for 1µg of mRNA 
The samples were incubated at 42 °C for 60 minutes then at 95 °C for 5 
minutes to terminate the reaction. 
3.2.4  Amplification of Target cDNA  
Detection RNA and miRNA was performed with Kappa Fast-SYBR Green 
(Peqlab). All reactions were set up in 96-well plate as shown in table 3.2-3 and 
table 3.2-4:  
 
 
 
 
 
Table 3.2-3 Total RNA mixture detection for one sample. 
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Table 3.2-4 Total miRNA mixture detection for one sample. 
All reactions were carried out by BioRad iCycler iQTM Real-Time PCR 
Detection System (Bio-Rad Laboratories, München, Germany) for 40 cycles, 
10-minute incubations at 95°C (95°C for 15 seconds, 60°C for 1 minute). Data 
analysis was carried out using the ΔΔCT method. L19 is a house-keeping gene 
which served as an internal control and was used to normalize for variances in 
input cDNA. All measurements were performed in triplicate. The following gene 
specific primer pairs for housekeeping L19, MKi67, RAC1, mi R-200a were 
designed using the Primer Blast software. 
Gene Primer Pairs 
L19 
  
forward (5'-3'): GCAGCCGGCGCAAA 
reverse (5'-3'): GCGGAAGGGTACAGCCAAT 
MKi67 
  
forward (5'-3'): CACACTCCACCTGTCCTGAA 
reverse (5'-3'): GACTAGGAGCTGGAGGGCTT 
Rac1 
  
forward (5'3'):TGCAGACACTTGCTCTCCTATGTAG 
reverse (5'-3'):GAGTTCAATGGCAACGCTTCA 
E-Cadherin 
  
forward (5'-3'): ACAACGACCCAACCCAAGAA 
reverse (5'-3'): TCACACACGCTGACCTCTAA 
 
Table3.2-5 The primers pair sequence. 
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3.2.5  Western blotting 
3.2.5.1 Protein Analysis 
3.2.5.1.1 Globular actin (G-actin) and filamentous actin (F-actin): 
Cells were cultured and grown in 6-well plate and treated as described. 
Ishikawa Cells briefly were washed once with Ice-cold PBS then removed. 100 
µl of ice-cold lysis Triton-X 100 extraction buffer was added and incubated on 
ice for 15 minutes. Soluble G protein was removed by aspiration and collected 
in 1.5ml tubes. Tubes were centrifuged at 13000 rpm for 15 min at 4 °C then 
stored in -20 °C. The Triton X-insoluble pellet (F-actin) was extracted by using 
100µl ice-cold RIPA buffer and collected in 1.5ml tubes. Tubes were centrifuged 
at 13000 rpm for 15 min at 4 °C ° and stored in -20 °C. 
To measure the amount of protein included in each sample, 800 ml of distilled 
water was added to 200 ml of Brad Ford (1:5 dilution) and 2µl of protein in the 
cuvette. The mixture was mixed by pipetting up and down and incubated in 
room temperature for 20 minutes then measured following the Bradford assay 
(Bio-Rad Laboratories) by the photometer. Equal amount of proteins (25µg) was 
diluted 1:1 loading buffer and denatured at 95 °C for 5 minutes. 
 
Figure 3.2-2 G-actin and F-actin extraction from Ishikawa cells. 
 
44 
 
3.2.5.1.2 Laemmli Buffer: 
Cells were treated as described. Cells were washed once with ice-cold PBS 
then protein was extracted using 400µl of hot Laemmli buffer (95 °C). Cells 
were scraped and transferred to 1.5ml tubes and heated to 95 °C for 15 
minutes. Samples were kept at -20 °C.  
 
3.2.5.2 SDS polyacrylamide gel electrophoresis (SDS-
PAGE) 
Proteins were separated on SDS-polyacrylamide gels and transferred using the 
Invitrogen XCell ll llTM Blot Module.  Gels were prepared from the solutions as 
shown in Table 3.2-6 to form the separating and the stacking gels. 
 
Table 3.2-6 Solutions volumes to prepare stacking and separating gels. 
 
The separating gel was poured into the empty gel cassettes until it reached 
approximately 2cm from the top and overlaid with saturated butan-2-ol. After 30 
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minutes the butan-2-ol was removed and the stacking gel was added on the 
separating gel and an appropriated comb inserted. Once the stacking gel had 
set the gel plate fitted into the electrophoresis tank and the running buffer x1 
was poured then the comb was removed. A Bradford assay (Bio-Rad 
Laboratories) determined the proteins concentration required to ensure equal 
protein loading (25µg). Spectra™ Multicolor Broad Range protein ladder marker 
was used and the samples were loaded in the wells. Gel was run in 1X Western 
SDS running buffer at 85 Voltage (V) for 30 minutes then the gel was resolved 
at 125 V for 60-90 minutes until the dye had migrated to the bottom of the gel. 
The gels were removed from the cassettes for transfer. 
3.2.5.3 Wet transfer 
The Invitrogen XCell II II™ Blot Module was used to transfer resolved proteins 
from a gel onto a polyvinylidene fluoride (PVDF). The PVDF transfer membrane 
was activated in 100% methanol. The gels, filtered papers and the PVDF were 
pre-soaked and equilibrated in Ice-cold Western transfer buffer. A sandwich 
was created as shown in (figure 3.2-3). A voltage gradient of 25 V and 230 mA 
was created perpendicular to the gel for 90 minutes. After transfer the PVDF 
membrane was air dried and the reactivated in 100% methanol.  
 
Figure 3.2-3 The sequence of Western blot sandwich components. 
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3.2.5.4 Blocking 
The membrane was blocked in 5% non-fat Milk for 1 hour at room temperature 
on a roller. After that the membrane was washed for 5 min in 1xTBS-T. The 
primary antibody (see table 2.2) was added to the membrane and kept on the 
roller at room temperature for 20 min then at 4 °C overnight. The next day the 
membrane was washed for 5 min in 1XTBS-T then 3 times, each 15 min in 
TBS-T. The secondary antibody was added for 1 hour at room temperature.  
Then washed once for 5 min in 1XTBS-T then 3 times, each 15 min in TBS-T. 
The membrane was subsequently exposed using Amersham Hybond-N+ 
autoradiology films. Protein complexes were visualized with ECL+ 
chemiluminescent detection kit (Amersham, Little Chalfont, UK). 
 
3.2.6  Flow Cytometry FACS 
3.2.6.1 Actin staining 
Ishikawa cells (≈1.0×106 cells) were treated as shown and washed three times 
with PBS then transferred into sterile 15 ml tubes. Then centrifuged at relative 
centrifugal force (rcf) 600 g for 5 minutes then the pellet was transferred into 
sterile 96 well-plates. Cells were fixed with 100 µl of 4% paraformaldehyde 
(PFA) and kept at room temperature in the dark for 15 minutes then 
permeabilised with 100µl of 1x Permeabilization buffer (eBioscience), and then 
centrifuged at rcf 600 g for 5 minutes. Cells were stained with 1 µl of fluorescent 
DNAse1-Alexaflour-488 (50mg/ml) for detection of G-Actin and fluorescent 
Phalloidin-eFluor® 660 (1000x) (eBioscience, Frankfurt, Germany) for detection 
of F-Actin and kept in dark at room temperature for 15 min then washed three 
times with ice-cold PBS. The abundance of the respective labels was measured 
using green (FL-1) and red channel (FL-4) on a FACSCalibur™ (BD 
Biosciences, Heidelberg, Germany) and analysis was performed using Flowjo 
software (Flowjo LLC, Oregon, USA). G and F actin geometric mean values 
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were determined from the respective fluorescence and the ratio of G/F 
calculated from the geometric mean values.  
3.2.6.2 BrdU (5-bromo-2`-deoxyuridine) staining 
The BrdU staining for flow cytometry was used for identifying and examining 
proliferating cells by flow cytometric analysis. BrdU (5-bromo-2`-deoxyuridine) is 
a synthetic analog of thymidine which incorporates into newly synthesized 
genomic DNA during the S-phase of mitosis. Then by following DNA 
denaturation, the cells were stained for BrdU incorporation along with any other 
cell surface and/or intracellular targets of interest. 
The BrdU staining was done based on BrdU staining for flow cytometry FITC 
(eBioscience). The cells were treated in 6-well plate as described. To harvest 
the cells 250 µl of trypsin was added, and cells were transferred to 15ml tubes 
and add PBS up to 10ml. Then centrifuged at 300xg for 5 min at room 
temperature. The PBS was removed from the tubes and the cells were 
transferred to 96-well plate. Then centrifuged at 300xg at room temperature for 
5 min. The plate was flicked and 200µl of Fixation Buffer was added and 
incubated at room temperature for 15 minutes, protected from light. After 
incubation, the plate was centrifuged at 300xg at room temperature for 5 min 
then washed twice with staining buffer. 25 µl DNase I was added to 75 µl of 
staining buffer and incubated at 37 °C for 1 hour, protected from light. The cells 
were washed twice with the staining buffer. For intracellular staining, 2 µl BrdU 
antibody was added and mixed gently and incubated at room temperature for 
30 minutes in the dark. Then centrifuged at 300xg at room temperature for 5 
min and then 200 µl of PBS was added to each sample and transferred to 
FACS tubes for analysis. 
 
3.2.6.3 Annexin V staining 
The Annexin staining was done based on Annexin V staining for flow cytometry 
(eBioscience). Ishikawa cells were treated in 6-well plate as described. Cells 
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were washed once with 200 µl of PBS, and once with 1 X binding buffer. Then 
cells were suspended in 150 µl of 1 X binding buffer and 2µl of fluorochrome-
conjugated Annexin V was added. The plate was incubated for 15 minutes at 
room temperature, protected from the light. Wash cells with 1 X binding buffer 
and Resuspend in 200 µl 1 X binding buffer then the cells were transferred to 
FACS tubes, and 2 µl of Propidium Iodide (PI) Staining Solution was added. 
The samples were analyzed with flow cytometry within 4 hours. 
 
3.2.7  Immunofluorescence for Confocal for Actin and 
E-CAD staining: 
Immunofluorescence is the method which is used to visualize a specific 
fluorescently labelled protein. Cells were treated and grown in sterile 4 –well 
Tissue culture chambers (Sarstedt) then were washed with ice-cold PBS once 
then fixed in 4% paraformaldehyde (PFA) for 15 minutes at room temperature. 
Cells were washed with ice-cold PBS x3 then permeabilised 10X 
Permeabilization buffer (eBioscience) for 15 minutes at room temperature.  
Actin staining: Actin was stained with eflour660-phalloidin (1:200, Invitrogen) 
for 1 hour at room temperature and with SYTOX® Green dye (1:5000, 
Invitrogen) for nuclei staining for 30 min in the dark then the slides were 
mounted with ProLong Gold antifade reagent (Invitrogen). 
E-Cadherin staining: E-CAD Primary antibody (diluted in Permeabilization 
buffer (1:100) was placed and kept at 4°C overnight. Cells were washed with 
ice-cold PBS (x4) then incubated with the secondary antibody (1:200) for 1hour 
at room temperature. Then wash three times with ice-cold PBS. Then DRAQ5TM 
(eBioscience), an anthraquinone nuclei dye with high affinity for double-
stranded DNA, was added. Finally, to mount ishikawa cells CC/Mount 
(SigmaTM) was added and the cover slip was placed. 
Confocal microscopy was performed with a confocal laser-scanning microscope 
(LSM 5 Exciter, Carl Zeiss, Germany) with a C-Apochromat 63/1.3 NA DIC 
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water immersion objective. The mean fluorescence from six related cells of 
each picture was quantified by ZEN software (Carl Zeiss, Germany) 
 
3.2.8  Migration assay: 
The Ishikawa Cells were counted and grown in sterile 6 well plates. Each well 
was scratched with sterile 10µl pipette tip then washed one time with PBS. 
Fresh 2% medium was placed and cells were treated as shown. The locations 
at which wounds were to be measured were marked with a marker on the 
undersurface of the wells to make sure that the measurements were taken from 
the same place. The wound width was measured by phase-contrast microscopy 
(Nikon Diaphot 300, Amsterdam, The Netherlands) immediately 0h and after 48 
h and photos were taken by Bresser Mikrocam (Bresser GmbH, Rhede, 
Germany) camera using MikroCamLab software. Data was analysed with 
ImageJ software. With ImageJ software the total area refers to the white area 
(the wound). Results were taken as 1-total area to refer to the black area (the 
cells), in other words to the migration. Wound closure was calculated and 
expressed as a percentage of initial wound width. 
 
 
 
 
Figure 3.2-4 Ishikawa Cells before (Left) and after (right) the artificial 
wound. 
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3.2.9 Statistics  
Results are provided as means ± SEM; n represents the quantity of 
independent experiments. Results were tested for significance depending on 
Student’s unpaired two-tailed t-test. The results with P <0.05 were referred as 
statistically significant.  
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4. Results 
The next two chapters of results were published in the following 2 articles.  
LeftyA decreases Actin Polymerization and Stiffness in Human 
Endometrial Cancer Cells.Salker MS, Schierbaum N, Alowayed N, Singh Y, 
Mack AF, Stournaras C, Schäffer TE, Lang F. Sci Rep. 2016 Jul 11;6:29370. 
doi: 10.1038/srep29370. 
LEFTY2 Controls Migration of Human Endometrial Cancer Cells via Focal 
Adhesion Kinase Activity (FAK) and miRNA-200a. Alowayed N, Salker MS, 
Zeng N, Singh Y, Lang F. Cell Physiol Biochem. 2016;39(3):815-26. doi: 
10.1159/000447792. Epub 2016 Aug 9. 
 
4.1 Results I 
4.1.1 The impact of LEFTY2 in Ishikawa cells stiffness 
by its effect on actin polymerization 
To test whether the role of LEFTY2 on cell shape, volume and stiffness was 
paralleled by the changing of actin polymerization dynamics, Ishikawa cells 
were incubated with LEFTY2 (25ng/ml) for 2 h then the ratio G-actin over F-
actin (G/F) was measured by Western blotting (A, B Fig.4.1-.1) and flow 
cytometry (C, D Fig.4.1-1). Significantly the amount of G-actin over F-actin 
increased, reflecting a depolymerization of actin in LEFTY2 treated ishikawa 
cells. Fluorescent images of F-actin organization and its concomitant changes 
under LEFTY2 show a profound reorganization of the actin cytoskeleton (E, F 
Fig.4.1-1). (as shown in Salker. et.al., 2016). 
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Figure 4.1-1 The effect of LEFTY2 on actin polymerization in Ishikawa cells 
(A) Representative Western blotting of soluble G-Actin over filamentous F-Actin in 
human endometrial cancer Ishikawa cells after a 2 hour treatment without (-LEFTY2) 
and with (+LEFTY2) Lefty A (25 ng/ml) (B) means ± SEM (n=6) of G-Actin over F-Actin 
ratio in Ishikawa cells after a 2 hour treatment without and with LEFTY2 (25 ng/ml). (C) 
Representative original histogram of DNase1 (G-Actin; Left) and Phalloidin (F-Actin; 
Right) binding in Ishikawa cells after a 2 hour treatment without (-LEFTY2) and with 
(+LEFTY2) LEFTY2 (25 ng/ml) (D) means ± SEM (n=6) of G-Actin over F-Actin ratio in 
Ishikawa cells after a 2 hours treatment without/with (white bar/black bar) LEFTY2 (25 
ng/ml).*, P<0.05; **, P<0.01; ***, P<0.001 by Student’s t-test. (E) Confocal figuers of 
eflour660- Phalloidin bind to F-Actin and SytoxGreen for nuclei (red and blue) in 
Ishikawa cells treated with/without LeftyA (white bar 20 μ m) (F) means ± SEM (n=6) of 
actin fluorescence in Ishikawa cells with and without LeftyA treatment (as shown in 
Salker. et.al., 2016).  
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4.1.2  LEFTY2 has a negative effect on Small G 
protein or GTPase RAC1 levels and activity 
Small G protein or GTPase Rac1 is a member of Rho family. Rac1 is known as 
a regulator for many different signaling pathways which are involved in 
cytoskeleton reorganization. It has the main role in lamellipodium formation 
during the cell motility. Rac1 overexpression was shown in many different 
classes of carcinomas and metastasis, which suggests Rac1 role in the 
pathogenesis of these cancers and the distant metastasis pointing to its role in 
cell migration. To test the role of LEFTY2 on Rac1 expression in Ishikawa cells 
we treated the cells with LEFTY2 (25ng/ml) for 2 hours. The treatment was 
followed significantly by downregulation of Rac1 transcript levels normalized to 
L19 transcript levels (Fig.4.1-2 A). The expression of Rac1 protein was also 
measured by Western blotting and showed a significant downregulation of total 
Rac1 and phospho Rac1 in LEFTY2 treated Ishikawa cells comparing to 
nontreated Ishikawa cells (Fig.4.1-2 B, C). (As shown in Salker. et.al., 2016).  
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Figure 4.1-2 The effect of LEFTY2 on Small G protein or GTPase Rac1 
(Rac1) transcript level and activity in Ishikawa cells. (A) means ±SEM (n=4) of 
Rac1 normalized to L19 transcript levels in human endometrial cancer Ishikawa cells 
following treatment with LEFTY2 (25ng/ml) for 2 hours. Data are shown as fold 
induction relative to transcript levels of untreated samples. *(P<0.05); **(P<0.01) 
indicate statistically significant difference, Students t-test. (B) Western- blots showing 
activated Rac1 & total Rac1 protein abundance in Ishikawa cells  after 2 h incubation 
without and with LEFTY2 (25 ng/ml). (C) means ±SEM (n=4) of phospho-Rac1 protein 
ratio normalized to GAPDH. *, P<0.05; **, P<0.01; ***, P<0.001 by Student’s t-test ( as 
shown in Salker. et.al., 2016).  
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4.1.3  The negative effect of LEFTY2 on RAC1 
indeed contributed to the polymerization of actin in 
Ishikawa cells 
 
After observing that LEFTY2 affected the cytoskeleton polymerization by 
downregulation the G/F ratio and LEFTY2 lead to a downregulation of Rac1 in 
Ishikawa cells. Rac1 is well acknowledged as a key regulator of various 
pathways that regulate the (re)organization of the cytoskeleton, we wanted to 
investigate whether this negative effect of LEFTY2 on Rac1 indeed contributed 
to the polymerization of actin in Ishikawa cells. To test that, Ishikawa cells were 
treated with LEFTY2 (25ng/ml) and with pharmacologic Rac1 inhibitor 
(NSC23766) trihydrochloride (100 µM) and with both LEFTY2 and Rac1 
inhibitor for 2 hours. The ratio G-Actin over F-Actin was measured by western 
Blotting (Fig.4.1-3; A,B) and flow cytometry (Fig.4.1-3; C,D). The treatment 
showed a significant rise of G/F actin in human endometrial cancer, an effect 
thus mimicking the effect of LEFTY2 treatment. In the presence of the Rac1 
inhibitor the additional administration of LEFTY2 (25 ng/ml) did not lead to a 
significant further rise of G-Actin over F-Actin Ratio in Ishikawa cells. (Fig.4.1-3) 
(as shown in Salker. et.al., 2016).  
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Figure 4.1-3 The effect of LEFTY2 on actin polymerization in Ishikawa in 
absence or presence of Rac1 inhibitor (A) Representative Western-blotting of G-
Actin over F-Actin in human endometrial cancer Ishikawa cells after a 2h treatment 
without and with LEFTY2 (25 ng/ml) in without/with Rac1 inhibitor NSC (100 µM). (B) 
means ± SEM (n=3) of G-Actin over F-Actin ratio in Ishikawa cells after a 2h treatment 
without/with LEFTY2 (25 ng/ml) without/with Rac1 inhibitor NSC23766 trihydrochloride 
(100µM). (C) Representative histogram of DNase1 (G actin; Upper) and Phalloidin (F 
actin; Lower) binding in Ishikawa cells after a 2h treatment without and with LEFTY2 
(25 ng/ml) without/with Rac1 inhibitor NSC23766 trihydrochloride (100µM). (D) means 
±SEM (n=5) of G-Actin/F-Actin ratio in Ishikawa cells after a 2h treatment without and 
with LEFTY2 (25 ng/ml) without/with Rac1 inhibitor NSC23766 trihydrochloride 
(100µM) *, P<0.05; **, P<0.01; ***, P<0.001 by Student’s t-test. (as shown in Salker. 
et.al., 2016).  
57 
 
4.1.4  The effect of LEFTY2 on p21 protein-activated 
kinase 1 (PAK1) expression Ishikawa cells 
Membrane- bound RAC1-GTP auto-phosphorylate PAK1. PAK1 expression has 
been studied in the endometrial cancer. It has been shown that PAK1 was 
overexpressed in this cancer comparing to the normal tissues pointing to its role 
in the pathogenesis of the endometrial cancer. PAK1 takes part in different 
cellular processes, e.g. the cytoskeleton polymerization and cells proliferation. 
To investigate whether LEFTY2 affects PAK1 expression in Ishikawa cells, 
treatment of LEFTY2 (25ng/ml) for 2 hours was applied. It shows that the 
expression of phospho PAK1 was downregulated in treating cells comparing to 
non-treating cells. This downregulation of PAK1 phosphorylation points to 
downregulation in the activity as well. (Fig.4.1-4). (as shown in Salker. et.al., 
2016). 
 
Figure4.1-4 The effect of LEFTY2 on phospho p21 protein-activated kinase 
1 (pPAK1) expression Ishikawa cells. Representative Western-blotting showing 
phospho PAK1 protein abundance in human endometrial cancer after 2h incubation 
without/with LEFTY2 (25 ng/ml) (as shown in Salker. et.al., 2016).  
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4.1.5  The negative effect of LEFTY2 on pPAK1 
indeed contributed to the polymerization of actin in 
Ishikawa cells 
Next series of experiments explored whether this decrease of PAK1 
phosphorylation indeed contributes the actin polymerization in Ishikawa cells. 
IPA-3 (50 μM), the pharmacological inhibition of PAK1, was followed by a 
significantly increase of G-actin over F-actin in human endometrial cancer 
Ishikawa cells, and the same effect has been shown with the treatment of 
LEFTY2 (25 ng/ml) for two hours (Fig.4.1-5) The doubled treatment of IPA-3 
and LEFTY2 was not followed by a significant increase of G/F-actin (as shown 
in Salker. et.al., 2016).  
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Figure 4.1-5 The effect of LEFTY2 on actin polymerization in Ishikawa in 
absence or presence of PAK1 inhibitor. (A) Representative Western blotting of 
G/actin over F/actin in human endometrial cancer Ishikawa cells after a 2-hour 
treatment without and with LEFTY2 (25ng/ml) in without/with PAK1 inhibitor IPA-3 (50 
µM). (B) Arithmetic means±SEM (n = 6) of G/actin over F/actin ratio in Ishikawa cells 
after a 2hour treatment without and with Lefty A (25ng/ml) in the absence and presence 
of the PAK1 inhibitor IPA-3 (50 µM). (C) Representative original histogram of DNase1 
(G actin; Upper) and Phalloidin (F actin; Lower) binding in Ishikawa cells after a 2-hour 
treatment without and with LEFTY2 (25 ng/ml) aswell without and with PAK1 inhibitor 
IPA-3 (50µM). (D) Arithmetic means ± SEM (n = 5; arbitrary units) of G/actin over 
F/actin ratio in Ishikawa cells after a 2hour treatment without and with LEFTY2 
(25ng/ml) without and with PAK1 inhibitor IPA-3 (50µM). *, P< 0.05; **, P<0.01; ***, 
P<0.001 using Students t-test (as shown in Salker. et.al., 2016).  
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4.1.6  The effect of LEFTY2 compared to 
Cytochalasin D 
The effect of LEFTY2 on Ishikawa cells was compared with the effect of 
Cytochalasin D, which induces the rapid actin depolymerisation. Ishikawa cells 
were treated with LEFTY2 (25ng/ml), and Cytochalasin D (10 μM, Sigma, 
Germany), LEFTY2 and Cytochalasin D for two hours. Treated-Ishikawa cells 
showed increase in the amount of G-actin over F-actin ratio reflecting 
depolymerization of the actin filaments compared to non-treated cells. (Fig 4.1-
6). (as shown in Salker. et.al., 2016).  
 
Figure 4.1-6 The effect of LEFTY2 on the actin polymerization compared to 
Cytochalasin D. Arithmetic means±SEM (n =4) of G actin over F actin ratio in 
Ishikawa cells after a 2hour treatment without (control) and with LEFTY2 (25 ng/ml) 
without and with Cytochalasin D (10 µM) *, P< 0.05;**, P<0.01;***,P<0.001 by 
Student’s t-test. (as shown in Salker. et.al., 2016).  
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4.1.7  The effect of LEFTY2 on actin filaments is 
temporary 
Treatment with LEFTY2 (25ng/ml) for two hours lead to increase in the amount 
of G actin over F actin in Ishikawa cells pointing to depolymerisation of actin 
filaments. To investigate whether this effect is permanent or long lasted, we 
treated Ishikawa cells with LEFTY2 (25ng/ml) for two hours and then G/F actin 
ratio was measured with FACS machine, once without washing and once with 
washing with normal medium for two hours. Interestingly, this effect of LEFTY2 
on the actin filaments was reversible in washed cells, pointing to temporary 
effect of LEFTY2. (Fig 4.1-7) (as shown in Salker. et.al., 2016). 
 
    
Figure 4.1-7 The effect of LEFTY2 on actin filaments in Ishikawa cells was 
temporary. Arithmetic means ± SEM (n =4) of G actin over F actin ratio in Ishikawa 
cells after a 2 hour treatment without (control) and with LEFTY2 (25 ng/ml) without 
wash (on the Left) and with wash (on the Right) *, P<0.05;**,P<0.01; ***, P<0.001 using 
Student’s t-test. (as shown in Salker. et.al., 2016).  
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4.2  Results II: 
 
4.2.1  LEFTY2 significantly decreased the transcript 
levels of the proliferation marker MKi67 
 
The next experiments explored effects of LEFTY2 on proliferation of human En 
Ca (Ishikawa) cells. To this end, Ishikawa cells were incubated with 25ng/ml of 
recombinant LEFTY2 for 48 hours. As illustrated in (Fig 4.2-1), LEFTY2 
significantly decreased the transcript levels of the proliferation marker MKi67. 
To investigate the effect of LEFTY2 during cell proliferation on Ishikawa cells 
BrdU assay was implemented. As shown in (Fig 4.2-1B), the proliferative ability 
of cells was decreased (34%) after a 48h treatment with LEFTY2. (as skhown in 
Alowayed. et.al., 2016). 
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Figure 4.2-1 LEFTY2 decreased the transcript levels of the proliferation 
marker MKi67. (A) means±SEM (n = 4) of MKi67 transcript levels. (B) Original FACS 
plot of BrdU staining (% of proliferative cells). C. Fold Change (%±SEM) of cell 
proliferation (n = 4). *(P<0.05) indicates significant difference, Student’s t-test. (as 
shown in Alowayed. et.al., 2016). 
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4.2.2  LEFTY2 significantly decreases migration in 
Ishikawa cells 
In order to test whether LEFTY2 affects migration, a wound-healing assay was 
performed. To this end, confluent Ishikawa cells were treated by mechanical 
wounding and subsequently treated with or without LEFTY2 (25ng/ml) for 48 
hours. Wound widths have been measured at 0 h and at 48 h, and wound 
closure was calculated (Fig. 4.2-2 A, B). Wound closure in the LEFTY2 treated 
cells was significantly lower when compared with the control-samples. (as shown 
in Alowayed. et.al., 2016). 
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Figure 4.2-2 LEFTY2 decreases migration in Ishikawa cells.  (A) Original 
photographs illustrating migration of human endometrial cancer Ishikawa cells without 
(left) and with (right) of LEFTY2 (25ng/ml) in a wound-healing assay (B) means±SEM 
(n=10) of the % of wound closure determined by image analysis without and with 
LEFTY2 (25ng/ml). ***(P<0.001) indicates significant difference, Student’s t-test. (as 
shown in Alowayed. et.al., 2016). 
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4.2.3  The effect of LEFTY2 on migration was 
paralleled by an influence on the activity of focal 
adhesion kinase (FAK) 
Next, the effect of LEFTY2 on cell migration was by of Focal Adhesion Kinase 
(FAK) was tested. To this end, confluent cultures were incubated as above and 
total protein lysates harvested for Western blot analysis. FAK activity was 
quantified from FAK-phosphorylation (Tyr397), utilizing a specific phospho 
antibody. Total FAK levels remained unchanged. As illustrated in (Fig 4.2-3 A, 
B), the incubated Ishikawa cells with LEFTY2 were followed by a significant 
reduction of FAK phosphorylation, in other words decreasing of FAK activity. (as 
shown in Alowayed. et.al., 2016). 
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Figure.4.2-3 The effect of LEFTY2 on migration was paralleled by an 
influence on the activity of focal adhesion kinase (FAK). (A) Representative 
original Western blots showing phosphorylated-FAK (Tyr397), total FAK and GAPDH 
protein abundance in human endometrial cancer cells after 48 h culture without and 
with LEFTY2 (25ng/ml). (B) means±SEM (n=4) of phosphorylated-FAK/ total FAK ratio 
normalized to GAPDH in the cells after 48 h culture without and with LEFTY2 
(25ng/ml). **(p<0.01) indicates significant difference from absence of LEFTY2; 
Student’s t-test. (as shown in Alowayed. et.al., 2016). 
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4.2.4  The effect of LEFTY2 on FAK activity with 
presence and absence of FAK inhibitor PF-573228 in 
Ishikawa cells 
In additional experiments Ishikawa cells were incubated for 48 h with LEFTY2 
(25 ng /ml) either with or without FAK inhibitor (PF 573228) (50µM) or left 
untreated (control). Western blotting was done to assess levels of total FAK and 
phosphorylated FAK (Tyr397). As shown in Figure 4.2-4, there was significantly 
reduction in phospho-FAK in cells treated with LEFTY2 with or without inhibitor 
PF 573228, compared to the control. No change was observed in total FAK 
levels (Fig4.2-4). (as shown in Alowayed. et.al., 2016). 
 
 
 
 
 
 
 
Figure 4.2-4 The effect of LEFTY2 on FAK activity with presence and 
absence of FAK inhibitor PF-573228 in Ishikawa cells. Representative original 
Western blots showing phosphorylated-FAK (Tyr397), total FAK and GAPDH protein 
abundance in human endometrial cancer cells after 48 h treatment without and with 
LEFTY2 (25ng/ml) ± FAK inhibitor PF-573228 (50 µM). (as shown in Alowayed. et.al., 
2016). 
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4.2.5  The inhibition of FAK phosphorylation was 
paralleled by inhibition of migration 
Next, we investigated whether inhibition of FAK phosphorylation was paralleled 
by inhibition of migration. To this end, a wound-healing assay was performed on 
Ishikawa cells treated with LEFTY2 with or without PF-573228 or control cells. 
As shown in Figure 4.2-5, the percentage of wound closure was significantly 
decreased 8% by a 48 hours treatment with FAK inhibitor PF 573228, which 
thus fully mimicked the effect of LEFTY2 on migration. The additional presence 
of LEFTY2 (25 ng/ml) did not lead to a further significant decrease of migratory 
activity, indicating that LEFTY2 was effective in large part by inhibiting FAK (Fig 
4.2-5 A, B). (as shown in Alowayed. et.al., 2016). 
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Figure 4.2-5 The inhibition of FAK phosphorylation was paralleled by 
inhibition of migration (A) Original photographs illustrating migration of human 
endometrial cancer Ishikawa cells without and with LEFTY2 (25ng/ml), FAK inh. PF-
573228 alone (50 µM) and LEFTY2 (25ng/ml) together with FAK inhibitor PF 573228 
(50 µM) at 0 h and 48 h . (B) means± SEM (n = 4) of the % of wound closure in the 
absence and presence of LEFTY2 (25ng/ml), FAK inhibitor PF 573228 (50 µM) and 
LEFTY2 (25ng/ml) together with FAK inhibitor PF 573228 (50 µM). 
**(P<0.01),***(P<0.001) indicates statistically significant difference, Student’s t-test. (as 
shown in Alowayed. et.al., 2016). 
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4.2.6  The effect of LEFTY2 on cell proliferation and 
apoptosis with and without the presence of FAK 
inhibitor. 
To investigate if the effect of migration was dependent upon cell proliferation, 
we performed qPCR for MKi67. As illustrated in (Fig. 4.2-6 A), incubation with 
LEFTY2 again decreased MKi67 transcript levels. However, treatment with the 
FAK inhibitor slightly decreased MKi67 levels, though not reaching statistical 
significance.  
Flourescently labeled Annexin V provides a method for studying the cellular-
apoptosis. FAK inhibitor (PF 573228) treated cells showed a slight increase in 
apoptotic cells (Fig 4.2-6 B) (as shown in Alowayed. et.al., 2016). 
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Figure 4.2-6 The effect of LEFTY2 on cell proliferation and apoptosis with 
and without the presence of FAK inhibitor. (A) Human endometrial cancer 
Ishikawa cells without and with LEFTY2 (25ng/ml), FAK inhibitor PF-573228 alone (50 
µM) and LEFTY2 (25ng/ml) together with FAK inhibitor PF-573228 (50 µM) for 48 
hours. Expression levels of MKi67 were measured using qRT-PCR. (B) In parallel 
experiments cells were subjected to Propidium Iodide (PI) and Annexin-V staining. 
Original FACS plots are shown. *P<0.05 indicates statistically significant difference, 
Student’s t-test. (as shown in Alowayed. et.al., 2016). 
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4.2.7  LEFTY2 influences the expression of E-cad 
and miRNA-200a 
Invasion and metastasis (migration) in carcinoma cells is associated with 
overexpression of FAK activity. Previously, it has been reported that migration is 
inhibited by adhesion molecule E-Cadherin which is upregulated by miRNA-
200. The next experiments determined whether LEFTY2 could affect the 
expression of E-cad and miRNA200-a in Ishikawa cells. To this end, Ishikawa 
cells either remained untreated or were treated with LEFTY2 (25ng/ml) with or 
without FAK inhibitor PF-573228 for a total of 48 hours and mRNA were 
collected. As a result, miR-200a was significantly upregulated in LEFTY2, PF-
573228 and LEFTY2+ PF 573228 treated cells compared to the control (Fig4.2-
7 A). In parallel cultures, confocal microscopy revealed that LEFTY2 with or 
without PF-573228 treatment further increased E-Cadherin protein abundance 
(Fig4.2-7 B) (as shown in Alowayed. et.al., 2016). 
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Figure 4.2-7 LEFTY2 influences the expression of E-cadherin and miRNA-
200a. (A) Human endometrial cancer cells without and with LEFTY2 (25ng/ml), FAK 
inhibitor PF-573228 alone (50 µM) and LEFTY2 (25ng/ml) together with FAK inhibitor 
PF 573228 (50 µM) for 48 hours. Expression levels of miR-200a/5S rRNA were 
measured using qRT-PCR. (B) Confocal Images of E-Cadherin (E-Cad) with and 
without LEFTY2 treatment with and without FAK inhibitor PF573228 (50 µM). Green (E-
Cad), Red (Draq5; nucleus). *P<0.05,**P<0.01 indicate statistically significant 
difference, Student’s t-test (as shown in Alowayed. et.al., 2016). 
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5. Discussion 
The discussion is based on my two publications: 
LEFTY2 Controls Migration of Human Endometrial Cancer Cells via Focal 
Adhesion Kinase Activity (FAK) and miRNA-200a. Alowayed N, Salker MS, 
Zeng N, Singh Y, Lang F. Cell Physiol Biochem. 2016;39(3):815-26. doi: 
10.1159/000447792. Epub 2016 Aug 9. 
 
LeftyA decreases Actin Polymerization and Stiffness in Human 
Endometrial Cancer Cells.Salker MS, Schierbaum N, Alowayed N, Singh Y, 
Mack AF, Stournaras C, Schäffer TE, Lang F. Sci Rep. 2016 Jul 11;6:29370. 
doi: 10.1038/srep29370. 
 
5.1 Discussion I 
LEFTY2 is a member of the TGF beta superfamily (Cornet et al., 2002). 
LEFTY2 active forms are able to inhibit TGF-β signaling (Cornet et al., 2002; 
Ulloa et al., 2001). It was shown that LEFTY2 can reprogram cancer cells 
(Cavallari et al., 2013), inhibiting cell proliferation, stimulating the apoptosis and 
thereby, suppression the tumor growth (Cavallari et al., 2013; Sun et al., 2014). 
These lines of data show LEFTY2 as a strong suppressor of tumor cell activity 
(Papageorgiou et al., 2009; Saito et al., 2013).  
The actin cytoskeleton provides the structural scaffold of a cell and mainly 
determines mechanical cellular properties (Bao and Suresh, 2003; Fletcher and 
Mullins, 2010) alteration of actin polymerization is in turn anticipated to modify 
cell stiffness. In this study, I observed that LEFTY2 significantly downregulated 
the cellular stiffness (Alesutan et al., 2013), volume and area compared to 
controls. I also showed that LEFTY2 has a negative effect of LEFYT2 on the 
actin filaments polymerization. Previously, researchers showed that the 
depolarization is related with a decrease in the stiffness of endothelial cells 
(Callies et al., 2011). In keeping with previous studies, I observed that LEFTY2 
significantly increased the G/F actin ratio pointing the powerful effect of LEFTY2 
in F actin filaments depolymerization compared to the controls.   
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LEFTY2 can inhibit Na+/H+ exchanger 1 (NHE1) activity (Salker et al., 2015). 
Regulators of NHE1 activity include Rac1 (Paradiso et al., 2004). Rac1 is a 
major controller of actin cytoskeleton and promotes the formation of lamellipodia 
(Nobes and Hall, 1995), the essential step for cell motility(Small et al., 2002). 
Rac1 can stimulate actin polymerization, either itself or by leading to auto-
phosphorylation of PAK1 (Papakonstanti and Stournaras, 2002; Ridley, 2006). I 
tested the role of LEFTY2 on Rac1 and PAK1. LEFTY2 downregulated Rac1 
and PAK1 expression and activity compared to the controls. In my study 
however, I showed that LEFYT2 can decrease of Rac1 (and PAK1) 
phosphorylation, indicating deactivation of these signaling effectors. Inhibition of 
these two key molecules is further expected to decrease of lamellipodia 
formation, which could explain the decrease of the cell area and volume. 
This effect of LEFTY2 was compared to cytochalasin D drug, the cytoskeletal 
drug which induces rapid actin depolymerization. Indeed, in keeping with 
previous findings, I observed that LEFTY2 showed an increase in the G/F actin 
ratio reflecting depolymerization of the actin filaments compared to controls. 
Interestingly, washing one group of the cells with normal medium showed that 
the effect of LEFTY2 was reversible pointing to the temporary and not 
permanent effect of LEFTY2. These rapid effects, were reversible upon 
washout, could reflect an early response of actin cytoskeleton dynamics in 
receiving and mediating extracellular signals as this was previously reported as 
well for cytokines, growth factors and steroid hormones.  
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5.2 Discussion II 
The results of the second part of this study uncover the negative role of LEFTY2 
on activation of FAK. FAK integrin-associated phosphorylation is a regulator of 
actin polymerization (Koukouritaki et al., 1999) through activating downstream 
molecules such as PAK1 (Manser et al., 1997). It regulates many cellular 
processes like (cell) growth, migration in normal & cancer cells, and cell shape 
and stiffness (Cohen and Guan, 2005; Guan et al., 1991; Mitra and Schlaepfer, 
2006; Schlaepfer et al., 2004). A previous study suggested, that decreased G/F 
actin in HUVECs is paralleled by a significant decrease in pFAK (Alesutan et al., 
2013). In my thesis, I observed the role of LEFTY2 on FAK expression and 
activity. In Ishikawa cells, LEFTY2 did not show any effect on total FAK levels. 
On the other hand, LEFTY2 significantly downregulated phospho FAK 
compared to controls, pointing to an inhibitory effect of LEFTY2 on FAK activity. 
FAK is located in the focal adhesions and makes a link between the ECM to the 
cytoskeleton (Mitra et al., 2005). Therefore, by regulating the activity of FAK, 
LEFTY2 could contribute to regulation of other physiological processes beyond 
regulating actin polymerization, cell stiffness and adhesion.  
Upregulation of FAK has been reported in endometrial hyperplasia and 
carcinoma pointing to its role in epithelial mesenchymal transition (EMT) and 
migration (van Nimwegen and van de Water, 2007; Zhao and Guan, 2011). 
EMT is the process by which the epithelial cells gain the properties of the 
mesenchymal cells by undergoing morphological changes (Kong et al., 2011; 
Thiery, 2002) and becomes more invasive. Deletion or inhibition of FAK impairs 
migration of fibroblasts (Mitra et al., 2005). In keeping with previous study, 
treatment with LEFTY2 or FAK inhibitor (PF-573228) decreases migration of 
Ishikawa cells. FAK inhibitor (PF 573228) treated cells showed a slight increase 
in apoptotic cells 
LEFTY2 is a suppressor of proliferation and a stimulator of cell death (Branford 
and Yost, 2004). In parallel with previous reports, this thesis observed the 
suppressor effect of LEFTY2 on the proliferation in Ishikawa cells. qPCR was 
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employed to measure the MKi67, the proliferation marker. LEFTY2 showed a 
significant decrease of MKi67 compared to controls. BrdU staining assay was 
performed to study the effect of LEFTY2 during Ishikawa cells proliferation. I 
observed that LEFTY2 significantly downregulated the proliferation compared to 
controls. The proliferative ability of the cells was decreased by 34% in LEFTY2 
treated cells compared to controls. 
It has been shown that overexpression of LEFTY2 antagonizes TGF-β signaling 
and blocks EMT-induced changes, including decrease E-cadherin in human 
proximal tubule epithelial cells (HK-2) (Li et al., 2010). MiRNA-200 family 
suppresses EMT by the upregulation of E-Cad and inhibits migration in BrCa 
cells and HeLa cells (Korpal et al., 2008). I explored further whether LEFTY2 
effects the expression of E-cadherin and miRNA-200, and I observed that 
treatment with LEFTY2 with or without FAK inhibitor was followed by a 
significant upregulation of miR-200a compared to the controls. LEFTY2 with or 
without FAK inhibitor treatment further increased E-Cadherin protein abundance 
compared to controls. That could explain another mechanism by which LEFTY2 
can inhibit cell migration. 
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5.3 Discussion III 
 
 
 
 
 
 
 
 
 
Figure 5.1 The suggested mechanisms of LEFTY2 on Ishikawa cells by which 
LEFTY2 may inhibit the migration of these cells. This figure is drawn by me as a 
summary of the results. 
 
It has been shown in this study; LEFTY2 has an inhibitory effect on Ishikawa 
cell migration. I suggest that LEFTY2 may influence the migration by different 
mechanisms. By affecting mechanically, the cytoskeleton and by making it 
smaller in volume and softer which could lead to weakness in the cells ability to 
migrate.  
Another mechanism could be, that LEFTY2 effects on Rac1 and PAK1 levels 
and activity, which are the trigger to cells motility process, by their critical role in 
the formation of the Lamellipodium which is considered as the first step in cell 
migration. 
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Reorganization of the cytoskeleton requires regulation of the actin proteins. 
LEFTY2 treated Ishikawa cells showed increase in G/F actin which points to the 
inhibitory effect on the polymerization of filamentous actin. This end could 
explain how LEFTY2 inhibits the formation of Lamellipodium which requires the 
elongation of F actin to apply the pressure on the cell membrane. 
FAK is a major intermediary of signalling cascades between cells and the ECM. 
Current findings show that FAK could have an important role in EMT and cell 
migration/invasion, in this study I further suggested that LEFTY2 could inhibit 
the signaling between cells and the ECM by inhibiting the FAK activity, which in 
turn could inhibit cell migration and the actin polymerization. I observed that the 
migration of cells was inhibited by LEFTY2 and/or by FAK inhibitor (PF 573228), 
pointing to the same pathway. 
LEFTY2 may inhibit the migration of Ishikawa cells by its inhibitory effect on the 
cell proliferation as it has been shown in the second part of this study. 
It has been revealed that TGFβ induces EMT. LEFTY2 can antagonise TGF- β 
signaling. I showed that LEFTY2 shows increases E-Cad and miRNA-200a in 
Ishikawa cells. This end suggests that LEFTY2 could antagonise TGF-β 
signaling in EMT.  
The ability of cancer cells to invade the surrounding tissue and to metastasize 
at a secondary site requires a highly dynamic reorganization of the actin 
cytoskeleton. By whatever mechanism, LEFTY2 inhibits the migration of 
Ishikawa cells, which could make LEFTY2 a novel therapeutic target in the 
future to inhibit the metastasis of primary endometrial carcinoma to the lymph 
nodes or inhibit invading the surrounding. The effect of LEFTY2 is temporary 
and not permanent which could make LEFTY2 a therapeutic target to inhibit 
cancer cells from metastasis by performing cyclic therapy. 
Clearly, further investigations are required to fully uncover role of LEFTY2 in 
EMT and the diverse process MET. 
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5.4 Future work: 
The exact mechanism of the negative effect of LEFTY2 on the ishikawa cell 
migration is still not totally understood. Further reserch is required to uncover 
the exact role of LEFTY2 in cancer progression and suppression.  
 This study has been done on Ishikawa cells in vitro. I suggest in the 
future studying the effect of LEFTY2 directly in the mouse models of 
cancer P53 with endometrial cancer to check the effect of LEFTY2 in 
vivo. 
 Another suggestion could be to obtain biopsies from the human 
endometrial cancer and check the levels of LEFTY2. 
 Previous study showed that the overexpression of LEFTY2 was absent in 
the adenocarcinomas of colon metastatic to the liver, that has not been 
studied in the endometrial cancer. I suggest checking the expression of 
LEFTY2 in the invaded lymph notes and in the distant metastasis of 
endometrial cancer.  
 Further research is required to check the effect of MiRNA 200-a 
treatment in Ishikawa cell on migration, the proliferation and the 
apoptosis.  
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5.5 Limitation of the study: 
During this study, I acquired a number of laboratory skills ranging from cell 
culture to qRT-PCR analysis, Western blot analysis, Immuno-staining and 
wound healing migration assay.  Neverless, I faced some small complications. 
For example, during migration study, the difficulty was in taking photos by the 
microscopy camera from the same wound region. This problem was easily 
resolved by taking three photos for each sample each time and analyse the 
data by taking the average. 
Furthermore, there was no access to clinical samples or to apply the treatment 
on mouse models. 
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6. Summary 
 This summary is based on the summary of the two publications of this 
study (Salker.et.al., 2016) and (Alowayed. et.al., 2016) as mentioned in 
the declaration. 
Cancer is unregulated cell growth with the ability to invade the neighboring 
tissues and could metastasize to distant organs. Endometrial carcinoma is an 
epithelial cancer which arises from the endometrium with a potential to invade 
the myometrium of the uterus or/ and the cervical stroma as well as. Each year, 
320 000 women worldwide are diagnosed with endometrial cancer and 76 000 
will die. An urgent medical innovation is required. 
In healthy endometrium, LEFTY2 is at low concentrations, but its expression 
levels are increased prior and during menstrual bleeding. LEFTY2 
overexpression is associated not only with infertility but also with dysfunctional 
uterine bleeding (DUB). 
LEFTY2 regulates stemness and embryonic differentiation. It is also able to 
down-regulate cellular growth and migration/invasion, which is dependant on 
actin re-organization. This process is controlled by Rac1 and PAK1.  
LEFTY2 can inhibit Na+/H+ exchanger1 (NHE1) activity. Regulators of NHE1 
activity include Rac1. NHE1 contributes further the stabilization and localization 
of actin. F-actin, plays a major role in maintenance cellular shape, therefore 
change of pH affect F-actin. 
This thesis tested whether LEFTY2 can modulate the cytoskeletal elements 
(G/F actin) in EnCa (Ishikawa cells). Changes in G over F Actin was tested by 
Western blotting and flow cytometry (FACS). We showed that LEFTY2 has an 
inhibitory role in the actin polymerization. We used quantativeRT-PCR method 
to measure the mRNA levels of Rac1 and PAK1, phospho Rac1 and PAK1 
were measured by immunoblotting. We show that a 2h treatment with LEFTY2 
significantly reduced the transcript levels and function of RAC1 and PAK1, 
leading to depolymerization of the actin filaments.  
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Further, the function of LEFTY2 on polymerization was mirrored inhibition of 
both Rac1 (NSC 23766) and PAK1 (IPA-3). LEFTY2 together with either of 
Rac1 / PAK1 inhibitors did not show further significant depolymerization of actin.  
We next tested whether LEFTY2 influences MKi67 (a celluler marker of 
proliferation), FAK activity, E-cad , and wound healing in our endometrial cancer 
cell line.  
We next tested miR-200a as a possible regulator of E-Cad. We show that 
LEFTY2 treatment reduces MKi67, FAK and wound healing. Further, this 2h 
treatment increased miR-200a and E-Cad levels. Finally, we show that inhibition 
with PF 573228 (FAK inhibitor) mirrored the effects of LEFTY2.  
In closing, this study describes the novel function of LEFTY2 in downregulating 
the activity of Rac1 & Pak1, which is follwed by rapid depolymerization. 
Furthermore, LEFTY2 reduced the expression of MKi67 and the function of 
FAK. On the other hand, LEFTY2 increased miR-200a and E-cad levels in 
keeping with its role as a negative controller of cellular proliferation and 
migration in EnCa. 
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Zusammenfassung 
Ungeregeltes Zellwachstum führt zur Krebserkrankung, die die Fähigkeit in 
Nachbargeweben einzudringen entwickelt und auf andere Organe 
metastasieren könnte. Das Endometriumkarzinom ist ein Epithelialkrebs, der 
aus dem Endometrium ausgeht, zum Myometrium der Gebärmutter oder / und 
dem zervikalen Stroma eindringen könnte. Jährlich wird bei 320000 Frauen 
weltweit das Endometriumkarzinom diagnostiziert und 76000 Frauen sterben 
daran. Eine therapeutische Intervention wird deshalb dringend benötigt.  
LEFTY2, auch Endometriumblutungen-assoziierter Faktor (EBAF) genannt, ist 
ein Mitglied der Transforming Growth Factor (TGF) -β Familie. LEFTY2 ist im 
gesunden Endometrium in geringer Konzentration vorhanden, aber das 
Expressionsniveau wird vor und während der Regelblutung erhöht. LEFTY2 
Überexpression steht nicht nur im Zusammenhang mit Unfruchtbarkeit, sondern 
auch mit einer dysfunktionalen uterinen Blutung (DUB). 
LEFTY2 reguliert den Stammzellenphänotyp und die embryonale 
Differenzierung und kann Zellproliferation und Migration hemmen. 
Zellproliferation und Motilität benötigen Aktinreorganisation, die unter der 
Kontrolle des ras-verwandten C3 Botulinumtoxin-Substrats 1 (Rac1) und p21-
Protein-activated kinase 1 (PAK1) stehen.  
LEFTY2 hemmt die Aktivität des Na + / H + Austauscher NHE1 und führt in 
Ishikawa-Zellen zu einer Verringerung des cytosolischen pH. NHE 1 Aktivität 
wird von Rac1 kontroliert. NHE1 trägt außerdem zur Stabilisierung und 
Lokalisierung von filamentösem Aktin (F-aktin) bei, das ein Zytoskelett- 
Struktur-Protein ist und eine entscheidende Rolle beim Aufrechterhalten der 
zellulären Form spielt.  
 
Die vorliegende Arbeit untersucht, ob LEFTY2 das Aktin-Zytoskelett, die Form 
und die Steifheit von Ishikawa-Zellen (eine gut differenzierte 
Endometriumkarzinom-Zelllinie) modulieren kann. Die Wirkung von LEFTY2 auf 
das globuläre/filamentäre Aktin-Verhältnis wurde unter der Verwendung von 
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Western-Blot und Durchflusszytometrie bestimmt. Wir zeigten, dass LEFTY2 
einen hemmenden Effekt auf die Aktin-Polymerisation hat. Rac1 und PAK1 
Transkriptlevel wurden mittels qRT-PCR und phospho Rac1 und PAK1 wurden 
mittels Immunoblotting gemessen. Nach 2 Stunden Behandlung mit LEFTY2 
(25 ng / ml) folgte eine signifikante Verringerung des Rac1 und PAK1 
Transkriptniveaus und Aktivität, und eine Depolymerisierung des Aktin. Ferner 
wurde der Effekt von LEFTY2 auf die Aktin-Polymerisation durch 
pharmakologische Hemmung von Rac1 und PAK1 nachgeahmt. LEFTY2 
zusammen mit Rac1 oder PAK1 Inhibitor führten zu keiner signifikanten 
weiteren Aktin-Depolymerisation. 
Maligne Transformation kann durch den Verlust von Zell-Zell-Adhäsion sowie 
durch Erwerb der Migrationseigenschaften zur Migration führen. Die 
Signaltransduktion inklusive von focal adhesion kinase (FAK) und 
Adhäsionsmoleküle E-Cadherin waren in der Migration, Proliferation und 
Verbreitung von Krebszellen involviert. 
 Wir untersuchten als nächstes, ob LEFTY2 die Proliferationsmarker MKi67, 
FAK-Aktivität, E-Cadherin Menge und die Migration von Ishikawa-Zellen 
beeinflusst. 
Darüber hinaus untersucht die Arbeit die Beteiligung von microRNA-200a (miR-
200a), die durch gezielte Beeinflußung von E-Cadherin, die Zelladhäsion 
reguliert. Zu diesem Zweck wurde FAK-Aktivität mittels FAK-Phosphorylierung 
durch Western blotting, Migration durch Verwendung eines Wundheilungs 
Assay, miR-200a und MKi67 Expressionsniveaus unter Verwendung von qRT-
PCR, Zellproliferation und Apoptose unter Verwendung von BrdU und Annexin 
V-Färbung bzw. und E-Cadherin (E-CAD) Menge, mit der konfokalen 
Mikroskopie untersucht. Als Ergebnis führte LEFTY2 (25 ng / ml, 48 Stunden) 
Behandlung zur Abnahme der MKi67 Expression, FAK-Aktivität sowie 
Migration. LEFTY2 steigert miRNA-200a und E-Cadherin levels in Ishikawa-
Zellen hoch. Die Wirkung von LEFTY2 auf Migration wurde mittels FAK-
Inhibitors (PF 573228) (50 µ M) bestätigt. Die Zugabe von LEFTY2 in 
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Gegenwart von PF-573228 führte nicht zu einem weiteren deutlichen Rückgang 
der Migration. 
Abschließend beschreibt diese Arbeit die neue Funktion von LEFTY2 bei der 
Herunterregulierung der Aktivität von Rac1 und Pak1, mit daraus resultierender 
Aktin Depolymerisation, Zell Steifigkeit und Zellschrumpfung. Darüberhinaus 
vermindert LEFTY2 die MKi67 Expression und die FAK-Aktivität, erhöht miR-
200a und E-Cadherin und zusammengefasst ist somit ein negativer Regulator 
der endometrialen Proliferation und Migration.  
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